Document And Entity Information
Document And Entity Information - USD ($) | 12 Months Ended | ||
Dec. 31, 2020 | Mar. 12, 2021 | Jun. 30, 2020 | |
Document Information [Line Items] | |||
Entity Registrant Name | VIVEVE MEDICAL, INC. | ||
Entity Central Index Key | 0000879682 | ||
Trading Symbol | vive | ||
Current Fiscal Year End Date | --12-31 | ||
Entity Filer Category | Non-accelerated Filer | ||
Entity Current Reporting Status | Yes | ||
Entity Voluntary Filers | No | ||
Entity Well-known Seasoned Issuer | No | ||
Entity Emerging Growth Company | false | ||
Entity Small Business | true | ||
Entity Interactive Data Current | Yes | ||
Entity Common Stock, Shares Outstanding (in shares) | 10,341,716 | ||
Entity Public Float | $ 8,858,275 | ||
Entity Shell Company | false | ||
Document Type | 10-K | ||
Document Period End Date | Dec. 31, 2020 | ||
Document Fiscal Year Focus | 2020 | ||
Document Fiscal Period Focus | FY | ||
Amendment Flag | false | ||
Title of 12(b) Security | Common Stock, par value $0.0001 per share |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) | Dec. 31, 2020 | Dec. 31, 2019 |
Current assets: | ||
Cash and cash equivalents | $ 6,523,000 | $ 13,308,000 |
Accounts receivable, net of allowance for doubtful accounts of $124 and $407 as of December 31, 2020 and 2019, respectively | 770,000 | 1,573,000 |
Inventory | 3,254,000 | 4,861,000 |
Prepaid expenses and other current assets | 2,296,000 | 2,447,000 |
Total current assets | 12,843,000 | 22,189,000 |
Property and equipment, net | 2,759,000 | 3,046,000 |
Investment in limited liability company | 833,000 | 1,216,000 |
Other assets | 195,000 | 526,000 |
Total assets | 16,630,000 | 26,977,000 |
Current liabilities: | ||
Accounts payable | 881,000 | 1,608,000 |
Accrued liabilities | 2,416,000 | 4,698,000 |
Paycheck Protection Program loan, current portion | 918,000 | |
Total current liabilities | 4,215,000 | 6,306,000 |
Note payable, noncurrent portion | 4,518,000 | 3,983,000 |
Paycheck Protection Program loan, noncurrent portion | 425,000 | |
Other noncurrent liabilities | 498,000 | 167,000 |
Total liabilities | 9,656,000 | 10,456,000 |
Commitments and contingences (Note 10) | ||
Stockholders’ equity: | ||
Common stock, $0.0001 par value; 75,000,000 shares authorized as of December 31, 2020 and December 31, 2019; 2,171,316 and 707,571 shares issued and outstanding as of December 31, 2020 and December 31, 2019, respectively | ||
Additional paid-in capital | 226,800,000 | 214,432,000 |
Accumulated deficit | (219,826,000) | (197,911,000) |
Total stockholders’ equity | 6,974,000 | 16,521,000 |
Total liabilities and stockholders’ equity | 16,630,000 | 26,977,000 |
Series A Preferred Stock [Member] | ||
Stockholders’ equity: | ||
Convertible preferred stock | ||
Series B Preferred Stock [Member] | ||
Stockholders’ equity: | ||
Convertible preferred stock |
Consolidated Balance Sheets (Pa
Consolidated Balance Sheets (Parentheticals) - USD ($) $ in Thousands | Dec. 31, 2020 | Dec. 31, 2019 |
Accounts receivable, allowance for doubtful accounts | $ 124 | $ 407 |
Convertible preferred stock, shares authorized (in shares) | 10,000,000 | 10,000,000 |
Common stock, par value (in dollars per share) | $ 0.0001 | $ 0.0001 |
Common stock, shares authorized (in shares) | 75,000,000 | 75,000,000 |
Common stock, shares issued (in shares) | 2,171,316 | 707,571 |
Common stock, shares outstanding (in shares) | 2,171,316 | 707,571 |
Series A Preferred Stock [Member] | ||
Convertible preferred stock, shares authorized (in shares) | 547,345 | |
Convertible preferred stock, par value (in dollars per share) | $ 0.0001 | $ 0.0001 |
Convertible preferred stock, shares issued (in shares) | 0 | 185,218 |
Convertible preferred stock, shares outstanding (in shares) | 0 | 185,218 |
Series B Preferred Stock [Member] | ||
Convertible preferred stock, par value (in dollars per share) | $ 0.0001 | $ 0.0001 |
Convertible preferred stock, shares issued (in shares) | 35,819 | 31,678 |
Convertible preferred stock, shares outstanding (in shares) | 35,819 | 31,678 |
Consolidated Statements of Oper
Consolidated Statements of Operations and Comprehensive Loss - USD ($) | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Revenue | $ 5,479,000 | $ 6,567,000 |
Cost of revenue | 5,183,000 | 5,551,000 |
Gross profit (loss) | 296,000 | 1,016,000 |
Operating expenses: | ||
Research and development | 5,125,000 | 8,590,000 |
Selling, general and administrative | 13,666,000 | 22,363,000 |
Restructuring costs | 742,000 | |
Total operating expenses | 18,791,000 | 31,695,000 |
Loss from operations | (18,495,000) | (30,679,000) |
Loss on debt restructuring | (6,705,000) | |
Modification of Series A and B warrants | (1,838,000) | |
Interest expense, net | (910,000) | (4,354,000) |
Other expense, net | (289,000) | (161,000) |
Net loss from consolidated companies | (21,532,000) | (41,899,000) |
Loss from minority interest in limited liability company | (383,000) | (627,000) |
Comprehensive and net loss | (21,915,000) | (42,526,000) |
Series B convertible preferred stock dividends | (4,149,000) | (380,000) |
Net loss attributable to common stockholders | $ (26,064,000) | $ (42,906,000) |
Net loss per share of common stock: | ||
Basic and diluted (in dollars per share) | $ (16.56) | $ (343.84) |
Weighted average shares used in computing net loss per common share: | ||
Basic and diluted (in shares) | 1,573,528 | 124,784 |
Consolidated Statements of Stoc
Consolidated Statements of Stockholders' Equity (Deficit) - USD ($) $ in Thousands | August 2019 ATM Facility [Member]Preferred Stock [Member]Series A Preferred Stock [Member] | August 2019 ATM Facility [Member]Preferred Stock [Member]Series B Preferred Stock [Member] | August 2019 ATM Facility [Member]Common Stock [Member] | August 2019 ATM Facility [Member]Additional Paid-in Capital [Member] | August 2019 ATM Facility [Member]Retained Earnings [Member] | August 2019 ATM Facility [Member] | November 2019 Offering [Member]Preferred Stock [Member]Series A Preferred Stock [Member] | November 2019 Offering [Member]Preferred Stock [Member]Series B Preferred Stock [Member] | November 2019 Offering [Member]Common Stock [Member] | November 2019 Offering [Member]Additional Paid-in Capital [Member] | November 2019 Offering [Member]Retained Earnings [Member] | November 2019 Offering [Member] | Purchase Agreement with LPC [Member]Preferred Stock [Member]Series A Preferred Stock [Member] | Purchase Agreement with LPC [Member]Preferred Stock [Member]Series B Preferred Stock [Member] | Purchase Agreement with LPC [Member]Common Stock [Member] | Purchase Agreement with LPC [Member]Additional Paid-in Capital [Member] | Purchase Agreement with LPC [Member]Retained Earnings [Member] | Purchase Agreement with LPC [Member] | Conversion of Series A Convertible Preferred Stock into Common Stock [Member]Preferred Stock [Member]Series A Preferred Stock [Member] | Conversion of Series A Convertible Preferred Stock into Common Stock [Member]Preferred Stock [Member]Series B Preferred Stock [Member] | Conversion of Series A Convertible Preferred Stock into Common Stock [Member]Common Stock [Member] | Conversion of Series A Convertible Preferred Stock into Common Stock [Member]Additional Paid-in Capital [Member] | Conversion of Series A Convertible Preferred Stock into Common Stock [Member]Retained Earnings [Member] | Conversion of Series A Convertible Preferred Stock into Common Stock [Member] | Conversion of Debt into Series B Convertible Preferred Stock and Common Stock [Member]Preferred Stock [Member]Series A Preferred Stock [Member] | Conversion of Debt into Series B Convertible Preferred Stock and Common Stock [Member]Preferred Stock [Member]Series B Preferred Stock [Member] | Conversion of Debt into Series B Convertible Preferred Stock and Common Stock [Member]Common Stock [Member] | Conversion of Debt into Series B Convertible Preferred Stock and Common Stock [Member]Additional Paid-in Capital [Member] | Conversion of Debt into Series B Convertible Preferred Stock and Common Stock [Member]Retained Earnings [Member] | Conversion of Debt into Series B Convertible Preferred Stock and Common Stock [Member] | Series A and Series B Warrants [Member]Preferred Stock [Member]Series A Preferred Stock [Member] | Series A and Series B Warrants [Member]Preferred Stock [Member]Series B Preferred Stock [Member] | Series A and Series B Warrants [Member]Common Stock [Member] | Series A and Series B Warrants [Member]Additional Paid-in Capital [Member] | Series A and Series B Warrants [Member]Retained Earnings [Member] | Series A and Series B Warrants [Member] | Series A-2 and Series B-2 Warrants [Member]Preferred Stock [Member]Series A Preferred Stock [Member] | Series A-2 and Series B-2 Warrants [Member]Preferred Stock [Member]Series B Preferred Stock [Member] | Series A-2 and Series B-2 Warrants [Member]Common Stock [Member] | Series A-2 and Series B-2 Warrants [Member]Additional Paid-in Capital [Member] | Series A-2 and Series B-2 Warrants [Member]Retained Earnings [Member] | Series A-2 and Series B-2 Warrants [Member] | Preferred Stock [Member]Series A Preferred Stock [Member] | Preferred Stock [Member]Series B Preferred Stock [Member] | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | Series B Preferred Stock [Member] | Total |
Balances (in shares) at Dec. 31, 2018 | 46,363 | ||||||||||||||||||||||||||||||||||||||||||||||||
Balances at Dec. 31, 2018 | $ 160,297 | $ (155,385) | $ 4,912 | ||||||||||||||||||||||||||||||||||||||||||||||
Stock offering, net of issuance costs (in shares) | 100,418 | 100,423 | 547,342 | 194,595 | |||||||||||||||||||||||||||||||||||||||||||||
Stock offering, net of issuance costs | $ 6,322 | $ 6,322 | $ 9,952 | $ 9,952 | |||||||||||||||||||||||||||||||||||||||||||||
Conversion of stock (in shares) | (362,124) | 362,124 | 31,300 | ||||||||||||||||||||||||||||||||||||||||||||||
Conversion of stock | $ 35,413 | $ 35,413 | |||||||||||||||||||||||||||||||||||||||||||||||
Series B convertible preferred stock dividends | (380) | (380) | |||||||||||||||||||||||||||||||||||||||||||||||
Series B convertible preferred stock dividends paid in PIK shares (in shares) | 378 | 378 | |||||||||||||||||||||||||||||||||||||||||||||||
Series B convertible preferred stock dividends paid in PIK shares | 378 | 378 | |||||||||||||||||||||||||||||||||||||||||||||||
Stock-based compensation expense | 2,251 | 2,251 | |||||||||||||||||||||||||||||||||||||||||||||||
Issuance of restricted common shares in connection with consulting agreement (in shares) | 3,869 | ||||||||||||||||||||||||||||||||||||||||||||||||
Issuance of restricted common shares in connection with consulting agreement | 75 | 75 | |||||||||||||||||||||||||||||||||||||||||||||||
Issuance of common shares from employee stock purchase plan (in shares) | 154 | ||||||||||||||||||||||||||||||||||||||||||||||||
Issuance of common shares from employee stock purchase plan | 56 | 56 | |||||||||||||||||||||||||||||||||||||||||||||||
Issuance of restricted stock awards to directors, employees and consultants (in shares) | 118 | ||||||||||||||||||||||||||||||||||||||||||||||||
Issuance of restricted stock awards to directors, employees and consultants | 74 | 74 | |||||||||||||||||||||||||||||||||||||||||||||||
Reverse stock split - cancellation and payout of fractional shares (in shares) | (70) | ||||||||||||||||||||||||||||||||||||||||||||||||
Reverse stock split - cancellation and payout of fractional shares | (6) | (6) | |||||||||||||||||||||||||||||||||||||||||||||||
Net loss | (42,526) | (42,526) | |||||||||||||||||||||||||||||||||||||||||||||||
Balances (in shares) at Dec. 31, 2019 | 185,218 | 31,678 | 707,571 | ||||||||||||||||||||||||||||||||||||||||||||||
Balances at Dec. 31, 2019 | 214,432 | (197,911) | 16,521 | ||||||||||||||||||||||||||||||||||||||||||||||
Balances (in shares) at Dec. 31, 2018 | 46,363 | ||||||||||||||||||||||||||||||||||||||||||||||||
Balances at Dec. 31, 2018 | 160,297 | (155,385) | 4,912 | ||||||||||||||||||||||||||||||||||||||||||||||
Series B convertible preferred stock dividends paid in PIK shares (in shares) | 4,519 | ||||||||||||||||||||||||||||||||||||||||||||||||
Balances (in shares) at Dec. 31, 2020 | 35,819 | 2,171,316 | |||||||||||||||||||||||||||||||||||||||||||||||
Balances at Dec. 31, 2020 | 226,800 | (219,826) | 6,974 | ||||||||||||||||||||||||||||||||||||||||||||||
Balances (in shares) at Dec. 31, 2019 | 185,218 | 31,678 | 707,571 | ||||||||||||||||||||||||||||||||||||||||||||||
Balances at Dec. 31, 2019 | 214,432 | (197,911) | 16,521 | ||||||||||||||||||||||||||||||||||||||||||||||
Stock offering, net of issuance costs (in shares) | 52,500 | ||||||||||||||||||||||||||||||||||||||||||||||||
Stock offering, net of issuance costs | 341 | 341 | |||||||||||||||||||||||||||||||||||||||||||||||
Conversion of stock (in shares) | (185,218) | 185,218 | |||||||||||||||||||||||||||||||||||||||||||||||
Conversion of stock | |||||||||||||||||||||||||||||||||||||||||||||||||
Series B convertible preferred stock dividends | (4,149) | (4,149) | |||||||||||||||||||||||||||||||||||||||||||||||
Series B convertible preferred stock dividends paid in PIK shares (in shares) | 4,141 | 4,141 | |||||||||||||||||||||||||||||||||||||||||||||||
Series B convertible preferred stock dividends paid in PIK shares | 4,141 | 4,141 | |||||||||||||||||||||||||||||||||||||||||||||||
Stock-based compensation expense | 2,577 | 2,577 | |||||||||||||||||||||||||||||||||||||||||||||||
Issuance of restricted common shares in connection with consulting agreement (in shares) | 10,995 | ||||||||||||||||||||||||||||||||||||||||||||||||
Issuance of restricted common shares in connection with consulting agreement | 74 | 74 | |||||||||||||||||||||||||||||||||||||||||||||||
Issuance of common shares from employee stock purchase plan (in shares) | 84 | ||||||||||||||||||||||||||||||||||||||||||||||||
Issuance of common shares from employee stock purchase plan | |||||||||||||||||||||||||||||||||||||||||||||||||
Issuance of restricted stock awards to directors, employees and consultants (in shares) | 25 | ||||||||||||||||||||||||||||||||||||||||||||||||
Net loss | (21,915) | (21,915) | |||||||||||||||||||||||||||||||||||||||||||||||
Issuance costs | $ (33) | $ (33) | $ (494) | $ (494) | |||||||||||||||||||||||||||||||||||||||||||||
Issuance of common shares in connection with warrant exercises (in shares) | 1,115,863 | 93,129 | |||||||||||||||||||||||||||||||||||||||||||||||
Issuance of common shares in connection with warrant exercises | $ 7,814 | $ 7,814 | $ 593 | $ 593 | |||||||||||||||||||||||||||||||||||||||||||||
Modification of Series A and B warrants in connection with 2020 Warrant Offering | $ 1,838 | $ 1,838 | |||||||||||||||||||||||||||||||||||||||||||||||
Issuance of Series A-2 and B-2 warrants in connection with 2020 Warrant Offering | 1,838 | 1,838 | |||||||||||||||||||||||||||||||||||||||||||||||
Transaction costs in connection with warrant offering | $ (1,838) | $ (1,838) | |||||||||||||||||||||||||||||||||||||||||||||||
Transaction costs in connection with warrant offering | (334) | (334) | |||||||||||||||||||||||||||||||||||||||||||||||
Restricted stock awards | |||||||||||||||||||||||||||||||||||||||||||||||||
Reverse stock split - rounding adjustment (in shares) | 5,931 | ||||||||||||||||||||||||||||||||||||||||||||||||
Balances (in shares) at Dec. 31, 2020 | 35,819 | 2,171,316 | |||||||||||||||||||||||||||||||||||||||||||||||
Balances at Dec. 31, 2020 | $ 226,800 | $ (219,826) | $ 6,974 |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows - USD ($) | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Cash flows from operating activities: | ||
Net loss | $ (21,915,000) | $ (42,526,000) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Provision for doubtful accounts | 454,000 | 1,028,000 |
Depreciation and amortization | 1,295,000 | 1,177,000 |
Stock-based compensation | 2,651,000 | 2,400,000 |
Non-cash interest expense | 535,000 | 1,577,000 |
Amortization of operating lease right-of-use assets and accretion of operating lease liabilities | 2,000 | 5,000 |
Loss on debt restructuring | 6,705,000 | |
Loss from minority interest in limited liability company | 383,000 | 627,000 |
Loss on disposal of property and equipment | 20,000 | 108,000 |
Modification of Series A and B warrants | 1,838,000 | |
Changes in assets and liabilities: | ||
Accounts receivable | 349,000 | 3,103,000 |
Inventory | 1,360,000 | (1,070,000) |
Prepaid expenses and other current assets | 151,000 | 111,000 |
Other noncurrent assets | 461,000 | 40,000 |
Accounts payable | (727,000) | (2,386,000) |
Accrued and other liabilities | (2,422,000) | (1,536,000) |
Other noncurrent liabilities | 331,000 | (599,000) |
Net cash used in operating activities | (15,234,000) | (31,236,000) |
Cash flows from investing activities: | ||
Purchase of property and equipment | (781,000) | (1,087,000) |
Net cash used in investing activities | (781,000) | (1,087,000) |
Cash flows from financing activities: | ||
Proceeds from exercise of common warrants | 8,407,000 | |
Transaction costs in connection with 2020 Warrant Offering | (334,000) | |
Proceeds from Paycheck Protection Program loan | 1,343,000 | |
Proceeds from intial purchase of common shares under Purchase Agreement with LPC | 341,000 | |
Proceeds from sale of common shares, net of issuance cost | 16,274,000 | |
Proceeds from issuance of common shares from employee stock purchase plan | 56,000 | |
Transaction costs in connection with note payable | (216,000) | |
Reverse stock split - cancellation and payout of fractional shares | (6,000) | |
Net cash provided by financing activities | 9,230,000 | 16,108,000 |
Net decrease in cash and cash equivalents | (6,785,000) | (16,215,000) |
Cash and cash equivalents - beginning of period | 13,308,000 | 29,523,000 |
Cash and cash equivalents - end of period | 6,523,000 | 13,308,000 |
Supplemental disclosure: | ||
Cash paid for interest | 2,508,000 | |
Cash paid for income taxes | ||
Supplemental disclosure of cash flow information as of end of period: | ||
Issuance of Series B convertible preferred stock in settlement of dividends | 4,141,000 | 378,000 |
Issuance of note payable in settlement of accrued interest | 532,000 | 1,226,000 |
Net transfer of equipment between inventory and property and equipment | 247,000 | 207,000 |
Issuance of Series B convertible preferred stock and common stock warrants in connection with debt conversion | 35,529,000 | |
Operating cash outflows from operating leases | 303,000 | 295,000 |
Right-of-use assets obtained in exchange for operating lease liabilities (upon adoption of ASC 842) | 629,000 | |
November 2019 Offering [Member] | ||
Cash flows from financing activities: | ||
Transaction costs in connection with November 2019 Offering | (33,000) | |
Purchase Agreement with LPC [Member] | ||
Cash flows from financing activities: | ||
Transaction costs in connection with November 2019 Offering | $ (494,000) |
Note 1 - The Company and Basis
Note 1 - The Company and Basis of Presentation | 12 Months Ended |
Dec. 31, 2020 | |
Notes to Financial Statements | |
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] | 1. The Company and Basis of Presentation Viveve Medical, Inc. (“Viveve Medical”, the “Company”, “we”, “our”, or “us”) designs, develops, manufactures and markets a platform medical technology, which we refer to as Cryogen-cooled Monopolar RadioFrequency 2021 On January 19, 2021, “January 2021 $27,600,000, In connection with the closing of the public offering, on January 19, 2021, no one The offering comprised of: ( 1 4,607,940 $3.40 one one one $3.40 fifth 2 2,450,880 $3.40 one one one $3.40 fifth 1,058,820 1,058,820 $25,223,000. A total of 2,450,880 January 2021 January 2021, no Elimination of Series A Convertible Preferred Stock On December 16, 2020, 547,345 $0.0001 November 25, 2019. no 547,345 Purchase Agreement with Lincoln Park Capital, LLC On June 8, 2020, $10,000,000 30 On June 9, 2020, 52,500 $6.50 may 25,000 50,000 12 no Other than as described above and Note 12 no 2020 On April 15, 2020, $15.50 $6.10 April 16, 2020, 482,059 24,279 $3,089,000. 2 482,059 2 24,279 $6.371 five April 20, 2020. 2020 $334,000. 12 December 31, 2020, 2 392,830 2 20,380 2019 In November 2019, “November 2019 $11,500,000, $9,922,000. The offering comprised of: ( 1 $15.50 one a one $15.50 first a one $15.50 fifth 2 $15.50 one one a one $15.50 first a one $15.50 fifth The securities comprising the units were immediately separable and were issued separately. A total of 194,595 547,345 741,939 741,939 December 31, 2020, no December 31, 2020, no December 31, 2020, 325,632 11 12 In connection with the closing of the November 2019 $28,981,000 $31,300,000, 31,300 989,379 7 5 120% $15.30 $18.36 one Liquidity and Management Plans Management evaluates whether there are relevant conditions and events that, in the aggregate, raise substantial doubt about the entity's ability to continue as a going concern and to meet its obligations as they become due within one The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. However, since inception, the Company has sustained significant operating losses and such losses are expected to continue for the foreseeable future. As of December 31, 2020, $219,826,000, $6,523,000 $8,628,000. $15,234,000 December 31, 2020. $9,230,000 December 31, 2020, March 31, 2022. December 31, 2020. January 2021 $25,223,000 $9,700,000 To fund further operations, the Company will need to raise additional capital. The Company may no not no |
Note 2 - Summary of Significant
Note 2 - Summary of Significant Accounting Policies | 12 Months Ended |
Dec. 31, 2020 | |
Notes to Financial Statements | |
Significant Accounting Policies [Text Block] | 2. Summary of Significant Accounting Policies Financial Statement Presentation The consolidated financial statements include the accounts of the Company and our wholly-owned subsidiaries, Viveve, Inc. and Viveve BV. All significant intercompany accounts and transactions have been eliminated in consolidation. Reverse Stock Split - December 2020 The Company effected a 1 10 December 1, 2020. ten one 75,000,000 As a result of the reverse stock split, proportionate adjustments were made to the per share exercise price and/or the number of shares issuable upon the exercise or vesting of all then outstanding stock options, deferred restricted stock awards and warrants, which will result in a proportional decrease in the number of shares of the Company's common stock reserved for issuance upon exercise or vesting of such stock options, deferred restricted stock awards and warrants, and, in the case of stock options and warrants, a proportional increase in the exercise price of all such stock options and warrants. In addition, the number of shares reserved for issuance under the Company's equity compensation plans immediately prior to the effective date will be reduced proportionately. The Company issued 5,931 No All of the share numbers, share prices, and exercise prices have been adjusted, on a retroactive basis, to reflect this 1 10 Reverse Stock Split - September 2019 The Company effected a 1 100 September 18, 2019. not No $6,000. The par value of the Company's common stock remained unchanged at $0.0001 The number of authorized shares of common stock remained at 75,000,000. The reverse stock split proportionately affected the number of shares of common stock available for issuance under the Company's equity incentive plans. All stock options, warrants and restricted stock awards of the Company outstanding shares immediately prior to the reverse stock split were adjusted in accordance with their terms. On the effective date of the reverse stock split, (i) each 100 one 100 1 1 100 100 1 All of the share numbers, share prices, and exercise prices have been adjusted, on a retroactive basis, to reflect this 1 100 Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses and the related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not may Changes in Accounting Policies Except for the changes for the adoption of the new accounting standard for leases, the Company has consistently applied the accounting policies to all periods presented in these consolidated financial statements. Adoption of New Accounting Standard-Leases The Company adopted FASB's Accounting Standards Update (“ASU”) No. 2016 02, 842 January 1, 2019, $629,000 $629,000, January 1, 2019. not not The effect of the changes made to our consolidated January 1, 2019 Adjustments Due to December 31, Adoption of January 1, 2018 ASC 842 2019 Other assets $ 171 $ 629 (1) $ 800 Total assets $ 46,834 $ 629 (1) $ 47,463 Accrued liabilities $ 6,766 $ 230 (2) $ 6,996 Total current liabilities $ 10,760 $ 230 (2) $ 10,990 Other noncurrent liabilities $ 634 $ 399 (2) $ 1,033 Total liabilities $ 41,922 $ 629 (2) $ 42,551 Total liabilities and stockholders' equity $ 46,834 $ 629 (2) $ 47,463 ( 1 Represents capitalization of operating lease right-of-use assets and reclassification of deferred rent. ( 2 Represents recognition of operating lease liabilities. Cash and Cash Equivalents The Company considers all highly liquid investments purchased with an original maturity of three one may, Concentration of Credit Risk and Other Risks and Uncertainties To achieve profitable operations, the Company must successfully develop, manufacture, and market its products. There can be no Most of the Company's products to date require clearance or approvals from the U.S. Food and Drug Administration (“FDA”) or other international regulatory agencies prior to commencing commercial sales. There can be no The Company is subject to risks common to companies in the medical device industry including, but not The Company designs, develops, manufactures and markets a medical device that it refers to as the Viveve System, which is intended for the non-invasive treatment of vaginal introital laxity, for improved sexual function, for vaginal rejuvenation, for use in general surgical procedures for electrocoagulation and hemostasis, and stress urinary incontinence, depending on the relevant country-specific clearance or approval. The Viveve System consists of three four five third In North America, the Company sells its products primarily through a direct sales force to health care practitioners. Outside North America, the Company sells through an extensive network of distribution partners. During the year ended December 31, 2020, one 36% December 31, 2019, one 16% There were no 10% December 31, 2020 2019. As of December 31, 2020, one 37% December 31, 2019, two 49% Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are recorded at the invoiced amount and are not six may six not $124,000 $407,000 December 31, 2020 2019, During the year ended December 31, 2020, $736,000 December 31, 2019, $905,000 Inventory Inventory is stated at the lower of cost or net realizable value. Inventory as of December 31, 2020 $2,818,000 $436,000 December 31, 2019 $4,051,000 $810,000 first first not As part of the Company's recurring revenue rental model, the Company utilizes Viveve Systems transferred from finished goods inventory. The Company is amortizing these units over an estimated useful life of five December 31, 2020 2019. As part of the Company's normal business, the Company generally utilizes various finished goods inventory as sales demos to facilitate the sale of its products to prospective customers. The Company is amortizing these demos over an estimated useful life of five December 31, 2020 2019. Property and Equipment, net Property and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over their estimated useful lives of three seven Impairment of Long-Lived Assets The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset might not not Revenue from Contracts with Customers Revenue consists primarily of the sale of the Viveve System, single-use treatment tips and ancillary consumables. The Company applies the following five 1 2 3 4 5 Rental revenue is generated through the lease of the Viveve System. The Company's operating leases for the Viveve System generally have a rental period of six nine June 30, 2019. December 31, 2020 2019, $1,337,000 $530,000. December 31, 2020 2019, $345,000 $662,000 December 31, 2020, $594,000 December 31, 2019. Late in the first 2020, 19 70 80% three 19 In connection with the lease of the Viveve System, the Company offers single-use treatment tips and ancillary consumables that are considered non-lease components. In the contracts with lease and non-lease components, the Company follows the relevant guidance in ASC 606, Sales of our products are subject to regulatory requirements that vary from country to country. The Company has regulatory clearance for differing indications, or can sell its products without a clearance, in many countries throughout the world, including countries within the following regions: North America, Latin America, Europe, the Middle East and Asia Pacific. In North America, we market and sell primarily through a direct sales force. Outside of North America, we market and sell primarily through distribution partners. The Company does not Customer Advance Payments From time to time, customers will pay for a portion of the products ordered in advance. Upon receipt of such payments, the Company records the customer advance payment as a component of accrued liabilities. The Company will remove the customer advance payment from accrued liabilities when revenue is recognized upon shipment of the products. Contract Assets and Liabilities The Company continually evaluates whether the revenue generating activities and advanced payment arrangements with customers result in the recognition of contract assets or liabilities. No December 31, 2020 2019. $17,000 $108,000, not December 31, 2020 December 31, 2019, The following table reflects the changes in our customer contract liabilities for the year ended December 31, 2020: December 31, December 31, 2020 2019 Change Customer contracts liabilities: Marketing programs $ 17 $ 108 $ (91 ) Total $ 17 $ 108 $ (91 ) Separately, accounts receivable, net represents receivables from contracts with customers. Significant Financing Component The Company applies the practical expedient to not not one December 31, 2020 2019, not Contract Costs The Company began its rental program in the quarter ended June 30, 2019. $132,000 $486,000 December 31, 2020 2019, December 31, 2020 2019, $417,000 $143,000, no Shipping and Handling Shipping costs billed to customers are recorded as revenue. Shipping and handling expense related to costs incurred to deliver product are recognized within cost of goods sold. The Company accounts for shipping and handling activities that occur after control has transferred as a fulfillment cost as opposed to a separate performance obligation, and the costs of shipping and handling are recognized concurrently with the related revenue. Revenue by Geographic Area: Management has determined that the sales by geography is a key indicator for understanding the Company's financials because of the different sales and business models that are required in the various regions of the world (including regulatory, selling channels, pricing, customers and marketing efforts). The following table presents the revenue from unaffiliated customers disaggregated by geographic area for the year ended December 31, 2020 2019 Year Ended December 31, 2020 2019 Asia Pacific $ 2,732 $ 2,349 United States 2,537 3,672 Canada 110 277 Europe and Middle East 86 254 Latin America 14 15 Total $ 5,479 $ 6,567 The Company determines geographic location of its revenue based upon the destination of the shipments of its products. Investments in Unconsolidated Affiliates The Company uses the equity method to account for its investments in entities that it does not 1 2 3 three not The Company assesses the potential impairment of the equity method investments when indicators such as a history of operating losses, a negative earnings and cash flow outlook, and the financial condition and prospects for the investee's business segment might indicate a loss in value. The carrying value of the investments is reviewed annually for changes in circumstances or the occurrence of events that suggest the investment may not December 31, 2020 2019, no Product Warranty The Company's products sold to customers are generally subject to warranties between one three not Advertising Costs Advertising costs are charged to selling, general and administrative expenses as incurred. Advertising expenses, which are recorded in selling, general and administrative expenses, were immaterial for the years ended December 31, 2020 2019. Research and Development Research and development costs are charged to operations as incurred. Research and development costs include, but are not Income Taxes The provision for income taxes is determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid. The provision for income taxes represents income taxes paid or payable for the current year plus the change in deferred taxes during the year. Deferred taxes result from differences between the financial and tax basis of the Company's assets and liabilities and are adjusted for changes in tax rates and tax laws when changes are enacted. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not not The Company must assess the likelihood that the Company's deferred tax assets will be recovered from future taxable income, and to the extent the Company believes that recovery is not December 31, 2020 2019. not not The Company recognizes in the financial statements the impact of a tax position, if that position is more likely than not not 12 Accounting for Stock-Based Compensation Share-based compensation cost is measured at grant date, based on the fair value of the award, and is recognized as expense over the employee's service period. The Company recognizes compensation expense on a straight-line basis over the requisite service period of the award. The Company determined that the Black-Scholes option pricing model is the most appropriate method for determining the estimated fair value for stock options and purchase rights under the employee stock purchase plan. The Black-Scholes option pricing model requires the use of highly subjective and complex assumptions which determine the fair value of share-based awards, including the option's expected term and the price volatility of the underlying stock. Equity instruments issued to nonemployees are recorded in the same manner as similar instruments issued to employees. Comprehensive Loss Comprehensive loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive loss may December 31, 2020 2019, Net Loss per Share The Company's basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. The diluted net loss per share is computed by giving effect to all potentially dilutive common stock equivalents outstanding during the period. For purposes of this calculation, stock options and warrants to purchase common stock and restricted common stock awards are considered common stock equivalents. For periods in which the Company has reported net losses, diluted net loss per share is the same as basic net loss per share, since dilutive common shares are not The following securities were excluded from the calculation of net loss per share because the inclusion would be anti-dilutive. December 31, 2020 2019 Convertible preferred stock: Series A convertible preferred stock - (a) 185,218 Series B convertible preferred stock 2,341,111 (b) 2,070,458 Warrants to purchase common stock 1,728,725 2,473,785 Stock options to purchase common stock 986,399 1,008,833 Deferred restricted common stock awards 394 277 (a) Each share of Series A convertible preferred stock was convertible at any time at the holder's option into one December 2020, December 31, 2020, no (b) As of December 31, 2020 2019, 35,819 31,678 2,341,111 2,70,458 1 65.36 $1,000 $15.30 not Other Recently Issued and Adopted Accounting Standards In November 2019, 2019 08, 718 606 718. December 15, 2019, January 1, 2020 not In December 2019, 2019 12, 740 December 15, 2020, January 1, 2021 not We have reviewed other recent accounting pronouncements and concluded they are either not no |
Note 3 - Fair Value Measurement
Note 3 - Fair Value Measurements | 12 Months Ended |
Dec. 31, 2020 | |
Notes to Financial Statements | |
Fair Value Disclosures [Text Block] | 3. Fair Value Measurements The Company recognizes and discloses the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 3 Level 1 Inputs used to measure fair value are unadjusted quoted prices that are available in active markets for the identical assets or liabilities as of the reporting date. Therefore, determining fair value for Level 1 not not Level 2 Pricing is provided by third not Level 3 Inputs used to measure fair value are unobservable inputs that are supported by little or no 3 Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company's assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. There were no December 31, 2020 2019. The carrying amounts of the Company's financial assets and liabilities, including cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses as of December 31, 2020 2019 There were no |
Note 4 - Property and Equipment
Note 4 - Property and Equipment, Net | 12 Months Ended |
Dec. 31, 2020 | |
Notes to Financial Statements | |
Property, Plant and Equipment Disclosure [Text Block] | 4. Property and Equipment, Net Property and equipment, net, consisted of the following as of December 31, 2020 2019 Life December 31, (in years) 2020 2019 Medical equipment 5 $ 3,111 $ 2,933 Rental program equipment 5 1,812 1,619 Computer equipment 3 242 243 Leasehold Improvements 3 122 122 Furniture and fixtures 7 386 385 Software 3 25 25 5,698 5,327 Less: Accumulated depreciation and amortization (2,939 ) (2,281 ) Property and equipment, net $ 2,759 $ 3,046 Depreciation and amortization expense for the years ended December 31, 2020 2019 $1,295,000 $1,177,000, |
Note 5 - Investment in Limited
Note 5 - Investment in Limited Liability Company | 12 Months Ended |
Dec. 31, 2020 | |
Notes to Financial Statements | |
Equity Method Investments and Joint Ventures Disclosure [Text Block] | 5. Investment in Limited Liability Company On August 8, 2017, Under the terms of the Distributorship Agreement, ICM agreed to not third not December 31, 2020 2019, 485 300 $51,000 $26,000 $52,000 $27,000 December 31, 2020 2019, no December 31, 2020 2019. In connection with the Distributorship Agreement, the Company also entered into a Membership Unit Subscription Agreement with ICM and the associated limited liability company operating agreement of ICM, pursuant to which the Company invested $2,500,000 not December 31, 2020, 7% three December 31, 2020 2019, $383,000 $627,000, In February 2019, no |
Note 6 - Accrued Liabilities
Note 6 - Accrued Liabilities | 12 Months Ended |
Dec. 31, 2020 | |
Notes to Financial Statements | |
Accounts Payable and Accrued Liabilities Disclosure [Text Block] | 6. Accrued Liabilities Accrued liabilities consisted of the following as of December 31, 2020 2019 December 31, December 31, 2020 2019 Accrued bonuses $ 744 $ 726 Accrued payroll and other related expenses 473 839 Deferred revenue - subscription rental program 345 662 Accrued professional fees 290 592 Current operating lease liabilities 132 268 Accrued inventory 87 474 Accrued sales commission 37 281 Customer contracts liabilities 17 108 Customer advances 14 53 Accrued interest 9 440 Other accruals 268 255 Total accrued liabilities $ 2,416 $ 4,698 |
Note 7 - Note Payable
Note 7 - Note Payable | 12 Months Ended |
Dec. 31, 2020 | |
Notes to Financial Statements | |
Debt Disclosure [Text Block] | 7. Note Payable On May 22, 2017, December 12, 2017 November 29, 2018 ( “2017 $20,000,000 $10,000,000 $30,000,000 December 29, 2017, $10,000,000 In connection with the 2017 two 10 223 $9,500.00 12 Under the 2017 November 12, 2019 six four 2017 12.5%, 4.0% may, December 31, 2019, $1,226,000, 5.0% As security for its obligations under the 2017 The terms of the 2017 2017 On November 12, 2019, 2017 No. 3” $28,981,000 $31,300,000. 31,300 989,379 5 120% $15.30 $18.36 12 one The Amendment No. 3 2017 ● repayment provisions were amended such that repayment is permitted only with, or after, the redemption in full of the Series B convertible preferred stock issued to CRG; ● the interest only payment period and the period during which the Company may 23rd first no 2017 ● modified certain of the covenants, including (i) to permit issuance of the Series B convertible preferred stock and any preferred stock issued in the equity financing and the exercise and performance by the Company of its rights and obligations in connection with such CRG preferred stock and any preferred stock issued in the equity financing, (ii) eliminate the Company's ability to enter into permitted acquisitions, (iii) further restrict the incurrence of additional indebtedness and removal of the equity cure right, and (iv) eliminate the minimum revenue requirement; and ● the back-end facility fee on the aggregate remaining principal balance on the term loan shall be increased from 5% 25%. Pursuant to the amendment, the Company paid interest in-kind of $532,000 December 31, 2020, As of December 31, 2020, As of December 31, 2020 2019, $4,518,000 $3,983,000 March 31, 2023. The Company accounted for the changes in the 2017 31,300 989,379 November 26, 2019 $1,023.23 $32,027,000. 11 $3,502,000 12 $6,705,000, December 31, 2019. As of December 31, 2020, Year Ending December 31, 2021 $ - 2022 - 2023 5,992 Total payments 5,992 Less: Amount representing interest (1,465 ) Present value of obligations 4,527 Less: Unamortized debt discount (9 ) Note payable, noncurrent portion $ 4,518 |
Note 8 - Paycheck Protection Pr
Note 8 - Paycheck Protection Program Loan | 12 Months Ended |
Dec. 31, 2020 | |
Notes to Financial Statements | |
Long-term Debt [Text Block] | 8. Paycheck Protection Program Loan The Paycheck Protection Program (“PPP”) was established under the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) and is administered by the U.S. Small Business Administration (“SBA”). On April 24, 2020, $1,343,000 1.00% two ten may No In October 2020, 8 24 six 10 16 no two October 2020. no As of December 31, 2020, Year Ending December 31, 2021 $ 938 2022 426 Total payments 1,364 Less: Amount representing interest (20 ) Present value of obligations 1,344 Paycheck Protection Program loan,current portion 918 Paycheck Protection Program loan, noncurrent portion $ 425 |
Note 9 - Leases
Note 9 - Leases | 12 Months Ended |
Dec. 31, 2020 | |
Notes to Financial Statements | |
Lessee, Operating Leases [Text Block] | 9. Leases Lessee: The following information pertains to those operating lease agreements where the Company is the lessee. On February 1, 2017, 12,400 January 26, 2017. June 1, 2017 May 2021. June 2017. The monthly base rent under the Sublease is equal to $20.50 first $21.12 $21.75 second third $22,000. $88,000 In September 2018, 36 September 20, 2018. $3,000. After the adoption of ASU 842 January 1, 2019, 12 not The following table reflects the Company's lease assets and lease liabilities at December 31, 2020 2019. December 31, December 31, 2020 2019 Assets: Operating lease right-of-use assets $ 130 $ 395 Liabilities: Current operating lease liabilities $ 132 $ 268 Noncurrent operating lease liabilities - 132 $ 132 $ 400 The operating lease right-of-use assets are included in other assets on the consolidated balance sheets. The operating lease liabilities are included in accrued liabilities and other noncurrent liabilities on the consolidated balance sheets. The operating lease expense for the years ended December 31, 2020 2019 $300,000 $301,000, As of December 31, 2020, Year Ending December 31, 2021 $ 137 Total lease payments 137 Less: Amount representing interest (5 ) Present value of lease liabilities $ 132 The weighted average remaining lease term was approximately 5 December 31, 2020. December 31, 2020 12.5%. Lessor: The following information pertains to those operating lease agreements where the Company is the lessor. As of December 31, 2020, Year Ending December 31, 2021 $ 345 Thereafter - Total $ 345 As of December 31, 2020, $841,000 December 31, 2020 2019 $462,000 $121,000, |
Note 10 - Commitments and Conti
Note 10 - Commitments and Contingencies | 12 Months Ended |
Dec. 31, 2020 | |
Notes to Financial Statements | |
Commitments and Contingencies Disclosure [Text Block] | 10. Commitments and Contingencies Indemnification Agreements The Company enters into standard indemnification arrangements in the ordinary course of business. Pursuant to these arrangements, the Company indemnifies, holds harmless and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with performance of services within the scope of the agreement, breach of the agreement by the Company, or noncompliance of regulations or laws by the Company, in all cases provided the indemnified party has not not not Loss Contingencies The Company is or has been subject to proceedings, lawsuits and other claims arising in the ordinary course of business. The Company evaluates contingent liabilities, including threatened or pending litigation, for potential losses. If the potential loss from any claim or legal proceeding is considered probable and the amount can be estimated, the Company accrues a liability for the estimated loss. Because of uncertainties related to these matters, accruals are based upon the best information available. For potential losses for which there is a reasonable possibility (meaning the likelihood is more than remote but less than probable) that a loss exists, the Company will disclose an estimate of the potential loss or range of such potential loss or include a statement that an estimate of the potential loss cannot be made. As additional information becomes available, the Company reassesses the potential liability related to pending claims and litigation and may not |
Note 11 - Preferred Stock
Note 11 - Preferred Stock | 12 Months Ended |
Dec. 31, 2020 | |
Notes to Financial Statements | |
Preferred Stock [Text Block] | 11. Preferred Stock Series A Convertible Preferred Stock In connection with the closing of a public offering, on November 26, 2019, With certain exceptions, as described in the Series A Certificate of Designation, the shares of Series A convertible preferred stock have no Each share of Series A convertible preferred stock is convertible at any time at the holder's option into one A total of 547,345 November 2019 November December 2019, 362,127 December 31, 2019, 185,218 January February 2020, 185,218 On December 16, 2020, no 547,345 Series B Convertible Preferred Stock As previously reported (see Note 7 31,300 989,379 In connection with the CRG debt conversion, on November 26, 2019, 12.5% December 31, 2019, 378 $2,000 December 31, 2020, 4,141 $8,000 December 31, 2020, 35,819 no We have paid approximately $10,000 4,519 December 31, 2020. The Series B convertible preferred stock provides that for so long as any shares are outstanding, the consent of the holders of the Series B convertible preferred stockholders would be required to amend the Company's organizational documents, approve any merger, sale of assets, or other major corporate transaction, or incur additional indebtedness, among other items. The fair value of the Series B convertible preferred stock was determined in connection with the CRG debt conversion as part of the accounting for that transaction as a troubled debt restructuring. Based on our valuation analysis, as of November 26, 2019, $1,023.23 $32,027,000 31,300 7 Under the terms of the Series B Preferred Stock and Warrant Purchase Agreement, as amended, CRG will not |
Note 12 - Common Stock
Note 12 - Common Stock | 12 Months Ended |
Dec. 31, 2020 | |
Notes to Financial Statements | |
Stockholders' Equity Note Disclosure [Text Block] | 12. Common Stock Purchase Agreement with Lincoln Park Capital, LLC On June 8, 2020, $10,000,000 30 On June 9, 2020, 52,500 $6.50 may 25,000 may 30,000 not $10 may 50,000 not $20 may not $1,000,000. no In addition to Regular Purchases described above, the Company may not three 3 30% 95% Under certain circumstances and in accordance with the Purchase Agreement, the Company may Other than as described above, there are no Transaction costs in connection with the Purchase Agreement with LPC totaled approximately $494,000. $325,000. no 2019 In November 2019, “November 2019 $11,500,000, $9,922,000. The offering comprised of: ( 1 $15.50 one one $15.50 first one $15.50 fifth 2 $15.50 one one one $15.50 first one $15.50 fifth The securities comprising the units were immediately separable and were issued separately. A total of 194,595 547,341 741,939 741,939 As of December 31, 2020, 11 As of December 31, 2020, no 325,632 ATM Equity Offerings Through the August 2019 may $6,760,000 $6,760,000 August 2019 September 2019. December 31, 2019, 100,423 August 2019 $6,322,000. December 31, 2019, no August 2019 In August 2019, November 2017 $25,000,000 December 31, 2019, zero November 2017 Restricted Common Shares The activity of restricted common shares for the year ended December 31, 2020 In March 2020, 2,832 $24,000. In June 2020, 3,453 $25,000. In September 2020, 4,709 $25,000. The activity of restricted common shares for the year ended December 31, 2019 In March 2019, 28 $25,000. In October 2019, 774 $25,000. In December 2019, 3,068 $25,000. Warrants for Common Stock As of December 31, 2020, Number of Shares Outstanding Exercisable Expiration Exercise Under Issuance Date for Date Price Warrants February 2015 Common Shares February 17, 2025 $ 4,000.00 79 March 2015 Common Shares March 26, 2025 $ 2,720.00 2 May 2015 Common Shares May 12, 2025 $ 4,240.00 37 December 2015 Common Shares December 16, 2025 $ 5,600.00 31 April 2016 Common Shares April 1, 2026 $ 6,080.00 25 May 2016 Common Shares May 11, 2021 $ 7,740.00 6 June 2016 Common Shares June 20, 2026 $ 4,980.00 101 May 2017 Common Shares May 25, 2027 $ 9,500.00 223 November 2019 Common Shares November 26, 2024 $ 6.10 325,632 November 2019 Common Shares November 26, 2024 $ 18.36 989,379 April 2020 Common Shares April 21, 2025 $ 6.37 413,210 1,728,725 As of December 31, 2019, Number of Shares Outstanding Exercisable Expiration Exercise Under Issuance Date for Date Price Warrants February 2015 Common Shares February 17, 2025 $ 4,000.00 79 March 2015 Common Shares March 26, 2025 $ 2,720.00 2 May 2015 Common Shares May 12, 2025 $ 4,240.00 37 May 2015 Common Shares May 17, 2020 $ 4,240.00 22 December 2015 Common Shares December 16, 2025 $ 5,600.00 31 April 2016 Common Shares April 1, 2026 $ 6,080.00 25 May 2016 Common Shares May 11, 2021 $ 7,740.00 6 June 2016 Common Shares June 20, 2026 $ 4,980.00 101 May 2017 Common Shares May 25, 2027 $ 9,500.00 223 November 2019 Common Shares November 26, 2020 $ 18.36 989,379 November 2019 Common Shares November 26, 2024 $ 15.50 741,940 November 2019 Common Shares November 26, 2024 $ 15.50 741,940 2,473,785 In connection with the November 2019 741,939 741,939 one $15.50 first one $15.50 fifth one one $15.50 one five $15.50 $1,210,000 0%, 91.1%, 1.59% one $2,871,000 0%, 68.8%, 1.58% five $4,081,000 November 2019 In February 2020, 102,626 $1,591,000, 4,548 $70,000. On April 15, 2020, $15.50 $6.10 $6.10 $15.50 April 15, 2020, 718, 718 $1,838,000 Immediately Immediately before Modification After Modification Exercise price $ 15.50 $ 6.10 Common stock price $ 6.30 $ 6.30 Expected term (in years) 2.8 2.8 Average volatility 97 % 97 % Risk-free interest rate 0.27 % 0.27 % Dividend yield 0 % 0 % On April 16, 2020, 482,059 24,279 $3,089,000. In conjunction, the Company also agreed to issue new Series A- 2 482,059 2 24,279 $6.371 five 2 2 $1,838,000 0%, 84.1%, of.35% five 2 2 April 20, 2020. 2020 $334,000. In May 2020, 410 $2,000. In June 2020, 2,761 $17,000, 5,070 $31,000. In August 2020, 111,704 $681,000, 380,913 $2,324,000. In August 2020, 89,230 2 $568,000, 3,899 2 $25,000. In September 2020, 1,500 $9,000. As of December 31, 2020, no 325,632 As of December 31, 2020, 2 392,830 2 20,380 In connection with the CRG Debt Conversion, CRG received warrants exercisable for 989,379 15% November 2019 five 120% $15.30 $18.36 $3,502,000 0%, 68.8%, 1.58% five In connection with the 2017 223 $9,500.00 ten $940,000 0%, 55.1%, 2.25% ten $790,000, December 31, 2020 2019, $3,000 $352,000, December 31, 2020, $9,000. During the year ended December 31, 2020, 1,209,000 $8,407,000. No December 31, 2019. No December 31, 2020 2019. A total of 42,404 December 31, 2020. 140 December 31, 2019. |
Note 13 - Summary of Stock Opti
Note 13 - Summary of Stock Options | 12 Months Ended |
Dec. 31, 2020 | |
Notes to Financial Statements | |
Share-based Payment Arrangement [Text Block] | 13. Summary of Stock Options Stock Option Plans The Company has issued equity awards in the form of stock options and restricted stock awards (“RSAs”) from two 2006 “2006 2013 “2013 As of December 31, 2020, 2006 12 no $9,920.00 2.1 The 2013 2013 2013 may may may 2013 may not 10 may four may 424 10% no 110% not five On August 22, 2016, 2013 first January, 2013 4% In January 2019, 2019 2013 2,044 4,914 6,958 January 1, 2019. In September 2019, 2013 18% 1 $5.0 2 December 31, 2019. 2013 1,187,253 November 26, 2019. In January 2020, 2020 2013 263,993 1,187,253 1,451,246 January 1, 2020. As of December 31, 2020, 2013 986,387 466,200 $18.98 8.9 Activity under the 2006 2013 Year Ended December 31, 2020 Weighted Weighted Average Number Average Remaining Aggregate of Exercise Contractual Intrinsic Shares Price Term (years) Value Options outstanding, January 1, 2019 4,098 $ 4,567.36 7.4 $ - Options granted 1,006,602 $ 11.42 Options exercised - Options canceled (1,867 ) $ 4,040.64 Options outstanding, December 31, 2019 1,008,833 $ 22.47 9.9 $ 3,928,715 Options granted 146,700 $ 6.36 Options exercised - Options canceled (169,134 ) $ 28.45 Options outstanding, December 31, 2020 986,399 $ 19.10 8.9 $ 675 Vested and exercisable and expected to vest, December 31, 2020 923,646 $ 19.77 8.9 $ 598 Vested and exercisable, December 31, 2020 245,445 $ 45.09 8.6 $ - The aggregate intrinsic value reflects the difference between the exercise price of the underlying stock options and the Company's closing share price as of December 31, 2020. The options outstanding and exercisable as of December 31, 2020 Weighted Number Weighted Average Number Weighted Outstanding Average Remaining Exercisable Average Range of as of Exercise Contractual as of Exercise Exercise Prices December 31, 2020 Price Term (Years) December 31, 2020 Price $4.45 - $8.91 967,288 $ 8.32 8.9 238,900 $ 8.69 $10.90 - $13.60 15,500 $ 12.64 9.2 3,750 $ 13.60 $380.00 - $580.00 125 $ 552.00 8.4 113 $ 567.61 $1,000.00 - $1,970.00 1,954 $ 1,426.46 7.6 1,334 $ 1,437.21 $2,020.00 - $2,830.00 74 $ 2,501.22 7.0 53 $ 2,520.19 $3,110.00 - $3,580.00 189 $ 3,439.26 7.6 156 $ 3,455.90 $4,360.00 - $4,970.00 619 $ 4,549.77 6.2 510 $ 4,554.04 $5,010.00 - $5,670.00 300 $ 5,366.00 6.2 285 $ 5,356.84 $6,000.00 - $6,000.00 138 $ 6,000.00 5.0 138 $ 6,000.00 $7,140.00 - $7,920.00 200 $ 7,679.20 4.1 194 $ 7,676.29 $9,920.00 - $9,920.00 12 $ 9,920.00 2.1 12 $ 9,920.00 Total: 986,399 $ 19.10 8.9 245,445 $ 45.09 Deferred Restricted Stock Awards As of December 31, 2020, 234 During the year ended December 31, 2020, no 2013 In June 2020, 25 June 2018. In July 2019, 38 2013 $380.80 38 In June 2019, 25 June 2018. In April 2019, 53 2013 $910.00 53 In January 2019, 384 2013 2018 2018 50% 50% December 31, 2020, 18 December 31, 2019, 132 December 31, 2020, zero 2017 In August 2017, 2017 “2017 may 200 2017 85% first three September 2020, 2017 twelfth September 30, 2020. During the years ended December 31, 2020 2019, 2017 84 154 $1,000 $56,000, The Company estimated the fair value of purchase rights under the ESPP using the Black-Scholes option valuation model and the straight-line attribution approach. As of December 31, 2020, 2017 22 Stock-Based Compensation During the years ended December 31, 2020 2019, 146,700 1,006,602 $4.08 $7.23 no December 31, 2020 2019. The Company estimated the fair value of stock options using the Black-Scholes option pricing model. The fair value of employee stock options is being amortized on a straight-line basis over the requisite service period of the awards. The fair value of employee stock options granted was estimated using the following weighted average assumptions: Year Ended December 31, 2020 2019 Expected term (in years) 5 6 Average volatility 82 % 70 % Risk-free interest rate 0.37 % 1.62 % Dividend yield - - Option-pricing models require the input of various subjective assumptions, including the option's expected life and the price volatility of the underlying stock. The expected stock price volatility is based on analysis of the Company's stock price history over a period commensurate with the expected term of the options, trading volume of comparable companies' stock, look-back volatilities and the Company specific events that affected volatility in a prior period. The expected term of stock options represents the weighted average period the stock options are expected to remain outstanding and is based on the history of exercises and cancellations on all past option grants made by the Company, the contractual term, the vesting period and the expected remaining term of the outstanding options. The risk-free interest rate is based on the U.S. Treasury interest rates whose term is consistent with the expected life of the stock options. No not not The following table shows stock-based compensation expense included in the consolidated statements of operations for the years ended December 31, 2020 2019 Year Ended December 31, 2020 2019 Cost of revenue $ 208 $ 135 Research and development 325 192 Selling, general and administrative 2,118 2,073 Total $ 2,651 $ 2,400 As of December 31, 2020, $4,781,000. 2.5 |
Note 14 - Income Taxes
Note 14 - Income Taxes | 12 Months Ended |
Dec. 31, 2020 | |
Notes to Financial Statements | |
Income Tax Disclosure [Text Block] | 14. Income Taxes No no The Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) was enacted on March 27, 2020 The Company's effective tax rate is 0% December 31, 2020 2019. A reconciliation of the U.S. statutory income tax rate to the Company's effective tax rate is as follows: Year Ended December 31, 2020 2019 Income tax benefit at statutory rate (21 )% (21 )% State income taxes, net of federal benefit (3 )% (4 )% Change in valuation allowance 20 % (39 )% Debt restructuring 0 % 6 % Limitation on net operating loss and credit carryovers 0 % 56 % Other 4 % 2 % Effective tax rate 0 % 0 % The components of the Company's net deferred tax assets and liabilities are as follows (in thousands): December 31, 2020 2019 Deferred tax assets: Net operating loss carryforwards $ 20,891 $ 16,688 Capitalized start up costs 2,866 3,225 Research and development credits 631 527 Accruals and reserves 773 532 Fixed assets and depreciation 291 128 Total deferred tax assets 25,452 21,100 Deferred tax liabilities: Valuation allowance (25,452 ) (21,100 ) Net deferred tax assets $ - $ - The Company has recorded a full valuation allowance for its deferred tax assets based on its past losses and the uncertainty regarding the ability to project future taxable income. The valuation allowance increased by approximately $4,352,000 December 31, 2020 $16,506,000 December 31, 2019. As of December 31, 2020, $95,395,000 $20,239,000, not 2028. The Company also has California research and development tax credits of approximately $817,000. no Utilization of the NOL and research and development credit carryforwards may 382 1986, may 382, 50 three November 2019, no As of December 31, 2020, not A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands): Year Ended December 31, 2020 2019 Balance at the beginning of the year $ 223 $ 450 Additions (deletions) based upon tax positions related to the current year 22 (227 ) Balance at the end of the year $ 245 $ 223 If the ending balance of $245,000 December 31, 2020 none not twelve may The Company files U.S. federal and state income tax returns with varying statutes of limitations. All tax years since inception remain open to examination due to the carryover of unused net operating losses and tax credits. |
Note 15 - Related Party Transac
Note 15 - Related Party Transactions | 12 Months Ended |
Dec. 31, 2020 | |
Notes to Financial Statements | |
Related Party Transactions Disclosure [Text Block] | 15. Related Party Transactions In June 2006, October 4, 2007. 300 December 31, 2020, 855 38 $1,051,000 $4,889,000 December 31, 2020 2019, In August 2017, February 2019, no 5 |
Note 16 - Segments and Geograph
Note 16 - Segments and Geographic Information | 12 Months Ended |
Dec. 31, 2020 | |
Notes to Financial Statements | |
Segment Reporting Disclosure [Text Block] | 16. Segments and Geographic Information The Company's long-lived assets by geographic area were as follows (in thousands): December 31, 2020 2019 United States $ 2,622 $ 2,818 Asia Pacific 76 64 Canada 54 142 Europe 7 22 Total $ 2,759 $ 3,046 Long-lived assets, comprised of property and equipment, are reported based on the location of the assets at each balance sheet date. |
Note 17 - Subsequent Events
Note 17 - Subsequent Events | 12 Months Ended |
Dec. 31, 2020 | |
Notes to Financial Statements | |
Subsequent Events [Text Block] | 17. Subsequent Events 2021 On January 19, 2021, “January 2021 $27,600,000, The offering comprised of: ( 1 4,607,940 $3.40 one one one $3.40 fifth 2 2,450,880 $3.40 one one one $3.40 fifth 1,058,820 1,058,820 $25,223,000. Series C Convertible Preferred Stock In connection with the closing of a public offering, on January 19, 2021, With certain exceptions, as described in the Series C Certificate of Designation, the shares of Series C convertible preferred stock have no Each share of Series C convertible preferred stock is convertible at any time at the holder's option into one A total of 2,450,880 January 2021 January 2021, no 2013 2021 Effective January 1, 2021, 2013 307,705 1,451,246 1,758,951 2013 November 2019 Amendment to Warrant Pricing Terms On January 19, 2021, $3.40 2 2 one $3.40. $6.10 $3.40 2 2 $6.371 $3.40 no Annual Equity Awards In January 2021, 690,000 2013 second Office Lease Amendment In March 2021, 34 March 31, 2024. second third $21,028, $21,643 $22,258 June 2021. $19,000. |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 12 Months Ended |
Dec. 31, 2020 | |
Accounting Policies [Abstract] | |
Basis of Accounting, Policy [Policy Text Block] | Financial Statement Presentation The consolidated financial statements include the accounts of the Company and our wholly-owned subsidiaries, Viveve, Inc. and Viveve BV. All significant intercompany accounts and transactions have been eliminated in consolidation. |
Reserve Stock Split, Policy [Policy Text Block] | Reverse Stock Split - December 2020 The Company effected a 1 10 December 1, 2020. ten one 75,000,000 As a result of the reverse stock split, proportionate adjustments were made to the per share exercise price and/or the number of shares issuable upon the exercise or vesting of all then outstanding stock options, deferred restricted stock awards and warrants, which will result in a proportional decrease in the number of shares of the Company's common stock reserved for issuance upon exercise or vesting of such stock options, deferred restricted stock awards and warrants, and, in the case of stock options and warrants, a proportional increase in the exercise price of all such stock options and warrants. In addition, the number of shares reserved for issuance under the Company's equity compensation plans immediately prior to the effective date will be reduced proportionately. The Company issued 5,931 No All of the share numbers, share prices, and exercise prices have been adjusted, on a retroactive basis, to reflect this 1 10 Reverse Stock Split - September 2019 The Company effected a 1 100 September 18, 2019. not No $6,000. The par value of the Company's common stock remained unchanged at $0.0001 The number of authorized shares of common stock remained at 75,000,000. The reverse stock split proportionately affected the number of shares of common stock available for issuance under the Company's equity incentive plans. All stock options, warrants and restricted stock awards of the Company outstanding shares immediately prior to the reverse stock split were adjusted in accordance with their terms. On the effective date of the reverse stock split, (i) each 100 one 100 1 1 100 100 1 All of the share numbers, share prices, and exercise prices have been adjusted, on a retroactive basis, to reflect this 1 100 |
Use of Estimates, Policy [Policy Text Block] | Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses and the related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not may |
Changes in Accounting Policies, Policy [Policy Text Block] | Changes in Accounting Policies Except for the changes for the adoption of the new accounting standard for leases, the Company has consistently applied the accounting policies to all periods presented in these consolidated financial statements. Adoption of New Accounting Standard-Leases The Company adopted FASB's Accounting Standards Update (“ASU”) No. 2016 02, 842 January 1, 2019, $629,000 $629,000, January 1, 2019. not not The effect of the changes made to our consolidated January 1, 2019 Adjustments Due to December 31, Adoption of January 1, 2018 ASC 842 2019 Other assets $ 171 $ 629 (1) $ 800 Total assets $ 46,834 $ 629 (1) $ 47,463 Accrued liabilities $ 6,766 $ 230 (2) $ 6,996 Total current liabilities $ 10,760 $ 230 (2) $ 10,990 Other noncurrent liabilities $ 634 $ 399 (2) $ 1,033 Total liabilities $ 41,922 $ 629 (2) $ 42,551 Total liabilities and stockholders' equity $ 46,834 $ 629 (2) $ 47,463 ( 1 Represents capitalization of operating lease right-of-use assets and reclassification of deferred rent. ( 2 Represents recognition of operating lease liabilities. |
Cash and Cash Equivalents, Policy [Policy Text Block] | Cash and Cash Equivalents The Company considers all highly liquid investments purchased with an original maturity of three one may, |
Concentration Risk, Credit Risk, Policy [Policy Text Block] | Concentration of Credit Risk and Other Risks and Uncertainties To achieve profitable operations, the Company must successfully develop, manufacture, and market its products. There can be no Most of the Company's products to date require clearance or approvals from the U.S. Food and Drug Administration (“FDA”) or other international regulatory agencies prior to commencing commercial sales. There can be no The Company is subject to risks common to companies in the medical device industry including, but not The Company designs, develops, manufactures and markets a medical device that it refers to as the Viveve System, which is intended for the non-invasive treatment of vaginal introital laxity, for improved sexual function, for vaginal rejuvenation, for use in general surgical procedures for electrocoagulation and hemostasis, and stress urinary incontinence, depending on the relevant country-specific clearance or approval. The Viveve System consists of three four five third In North America, the Company sells its products primarily through a direct sales force to health care practitioners. Outside North America, the Company sells through an extensive network of distribution partners. During the year ended December 31, 2020, one 36% December 31, 2019, one 16% There were no 10% December 31, 2020 2019. As of December 31, 2020, one 37% December 31, 2019, two 49% |
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block] | Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are recorded at the invoiced amount and are not six may six not $124,000 $407,000 December 31, 2020 2019, During the year ended December 31, 2020, $736,000 December 31, 2019, $905,000 |
Inventory, Policy [Policy Text Block] | Inventory Inventory is stated at the lower of cost or net realizable value. Inventory as of December 31, 2020 $2,818,000 $436,000 December 31, 2019 $4,051,000 $810,000 first first not As part of the Company's recurring revenue rental model, the Company utilizes Viveve Systems transferred from finished goods inventory. The Company is amortizing these units over an estimated useful life of five December 31, 2020 2019. As part of the Company's normal business, the Company generally utilizes various finished goods inventory as sales demos to facilitate the sale of its products to prospective customers. The Company is amortizing these demos over an estimated useful life of five December 31, 2020 2019. |
Property, Plant and Equipment, Policy [Policy Text Block] | Property and Equipment, net Property and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over their estimated useful lives of three seven |
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] | Impairment of Long-Lived Assets The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset might not not |
Revenue from Contract with Customer [Policy Text Block] | Revenue from Contracts with Customers Revenue consists primarily of the sale of the Viveve System, single-use treatment tips and ancillary consumables. The Company applies the following five 1 2 3 4 5 Rental revenue is generated through the lease of the Viveve System. The Company's operating leases for the Viveve System generally have a rental period of six nine June 30, 2019. December 31, 2020 2019, $1,337,000 $530,000. December 31, 2020 2019, $345,000 $662,000 December 31, 2020, $594,000 December 31, 2019. Late in the first 2020, 19 70 80% three 19 In connection with the lease of the Viveve System, the Company offers single-use treatment tips and ancillary consumables that are considered non-lease components. In the contracts with lease and non-lease components, the Company follows the relevant guidance in ASC 606, Sales of our products are subject to regulatory requirements that vary from country to country. The Company has regulatory clearance for differing indications, or can sell its products without a clearance, in many countries throughout the world, including countries within the following regions: North America, Latin America, Europe, the Middle East and Asia Pacific. In North America, we market and sell primarily through a direct sales force. Outside of North America, we market and sell primarily through distribution partners. The Company does not Customer Advance Payments From time to time, customers will pay for a portion of the products ordered in advance. Upon receipt of such payments, the Company records the customer advance payment as a component of accrued liabilities. The Company will remove the customer advance payment from accrued liabilities when revenue is recognized upon shipment of the products. Contract Assets and Liabilities The Company continually evaluates whether the revenue generating activities and advanced payment arrangements with customers result in the recognition of contract assets or liabilities. No December 31, 2020 2019. $17,000 $108,000, not December 31, 2020 December 31, 2019, The following table reflects the changes in our customer contract liabilities for the year ended December 31, 2020: December 31, December 31, 2020 2019 Change Customer contracts liabilities: Marketing programs $ 17 $ 108 $ (91 ) Total $ 17 $ 108 $ (91 ) Separately, accounts receivable, net represents receivables from contracts with customers. Significant Financing Component The Company applies the practical expedient to not not one December 31, 2020 2019, not Contract Costs The Company began its rental program in the quarter ended June 30, 2019. $132,000 $486,000 December 31, 2020 2019, December 31, 2020 2019, $417,000 $143,000, no Shipping and Handling Shipping costs billed to customers are recorded as revenue. Shipping and handling expense related to costs incurred to deliver product are recognized within cost of goods sold. The Company accounts for shipping and handling activities that occur after control has transferred as a fulfillment cost as opposed to a separate performance obligation, and the costs of shipping and handling are recognized concurrently with the related revenue. Revenue by Geographic Area: Management has determined that the sales by geography is a key indicator for understanding the Company's financials because of the different sales and business models that are required in the various regions of the world (including regulatory, selling channels, pricing, customers and marketing efforts). The following table presents the revenue from unaffiliated customers disaggregated by geographic area for the year ended December 31, 2020 2019 Year Ended December 31, 2020 2019 Asia Pacific $ 2,732 $ 2,349 United States 2,537 3,672 Canada 110 277 Europe and Middle East 86 254 Latin America 14 15 Total $ 5,479 $ 6,567 The Company determines geographic location of its revenue based upon the destination of the shipments of its products. |
Equity Method Investments [Policy Text Block] | Investments in Unconsolidated Affiliates The Company uses the equity method to account for its investments in entities that it does not 1 2 3 three not The Company assesses the potential impairment of the equity method investments when indicators such as a history of operating losses, a negative earnings and cash flow outlook, and the financial condition and prospects for the investee's business segment might indicate a loss in value. The carrying value of the investments is reviewed annually for changes in circumstances or the occurrence of events that suggest the investment may not December 31, 2020 2019, no |
Standard Product Warranty, Policy [Policy Text Block] | Product Warranty The Company's products sold to customers are generally subject to warranties between one three not |
Advertising Cost [Policy Text Block] | Advertising Costs Advertising costs are charged to selling, general and administrative expenses as incurred. Advertising expenses, which are recorded in selling, general and administrative expenses, were immaterial for the years ended December 31, 2020 2019. |
Research and Development Expense, Policy [Policy Text Block] | Research and Development Research and development costs are charged to operations as incurred. Research and development costs include, but are not |
Income Tax, Policy [Policy Text Block] | Income Taxes The provision for income taxes is determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid. The provision for income taxes represents income taxes paid or payable for the current year plus the change in deferred taxes during the year. Deferred taxes result from differences between the financial and tax basis of the Company's assets and liabilities and are adjusted for changes in tax rates and tax laws when changes are enacted. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not not The Company must assess the likelihood that the Company's deferred tax assets will be recovered from future taxable income, and to the extent the Company believes that recovery is not December 31, 2020 2019. not not The Company recognizes in the financial statements the impact of a tax position, if that position is more likely than not not 12 |
Share-based Payment Arrangement [Policy Text Block] | Accounting for Stock-Based Compensation Share-based compensation cost is measured at grant date, based on the fair value of the award, and is recognized as expense over the employee's service period. The Company recognizes compensation expense on a straight-line basis over the requisite service period of the award. The Company determined that the Black-Scholes option pricing model is the most appropriate method for determining the estimated fair value for stock options and purchase rights under the employee stock purchase plan. The Black-Scholes option pricing model requires the use of highly subjective and complex assumptions which determine the fair value of share-based awards, including the option's expected term and the price volatility of the underlying stock. Equity instruments issued to nonemployees are recorded in the same manner as similar instruments issued to employees. |
Comprehensive Income, Policy [Policy Text Block] | Comprehensive Loss Comprehensive loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive loss may December 31, 2020 2019, |
Earnings Per Share, Policy [Policy Text Block] | Net Loss per Share The Company's basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. The diluted net loss per share is computed by giving effect to all potentially dilutive common stock equivalents outstanding during the period. For purposes of this calculation, stock options and warrants to purchase common stock and restricted common stock awards are considered common stock equivalents. For periods in which the Company has reported net losses, diluted net loss per share is the same as basic net loss per share, since dilutive common shares are not The following securities were excluded from the calculation of net loss per share because the inclusion would be anti-dilutive. December 31, 2020 2019 Convertible preferred stock: Series A convertible preferred stock - (a) 185,218 Series B convertible preferred stock 2,341,111 (b) 2,070,458 Warrants to purchase common stock 1,728,725 2,473,785 Stock options to purchase common stock 986,399 1,008,833 Deferred restricted common stock awards 394 277 (a) Each share of Series A convertible preferred stock was convertible at any time at the holder's option into one December 2020, December 31, 2020, no (b) As of December 31, 2020 2019, 35,819 31,678 2,341,111 2,70,458 1 65.36 $1,000 $15.30 not |
New Accounting Pronouncements, Policy [Policy Text Block] | Other Recently Issued and Adopted Accounting Standards In November 2019, 2019 08, 718 606 718. December 15, 2019, January 1, 2020 not In December 2019, 2019 12, 740 December 15, 2020, January 1, 2021 not We have reviewed other recent accounting pronouncements and concluded they are either not no |
Note 2 - Summary of Significa_2
Note 2 - Summary of Significant Accounting Policies (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Notes Tables | |
Cumulative Effect of Adjustments for New Accounting Pronouncements on Balance Sheet [Table Text Block] | Adjustments Due to December 31, Adoption of January 1, 2018 ASC 842 2019 Other assets $ 171 $ 629 (1) $ 800 Total assets $ 46,834 $ 629 (1) $ 47,463 Accrued liabilities $ 6,766 $ 230 (2) $ 6,996 Total current liabilities $ 10,760 $ 230 (2) $ 10,990 Other noncurrent liabilities $ 634 $ 399 (2) $ 1,033 Total liabilities $ 41,922 $ 629 (2) $ 42,551 Total liabilities and stockholders' equity $ 46,834 $ 629 (2) $ 47,463 |
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] | December 31, December 31, 2020 2019 Change Customer contracts liabilities: Marketing programs $ 17 $ 108 $ (91 ) Total $ 17 $ 108 $ (91 ) |
Revenue from External Customers by Geographic Areas [Table Text Block] | Year Ended December 31, 2020 2019 Asia Pacific $ 2,732 $ 2,349 United States 2,537 3,672 Canada 110 277 Europe and Middle East 86 254 Latin America 14 15 Total $ 5,479 $ 6,567 |
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] | December 31, 2020 2019 Convertible preferred stock: Series A convertible preferred stock - (a) 185,218 Series B convertible preferred stock 2,341,111 (b) 2,070,458 Warrants to purchase common stock 1,728,725 2,473,785 Stock options to purchase common stock 986,399 1,008,833 Deferred restricted common stock awards 394 277 |
Note 4 - Property and Equipme_2
Note 4 - Property and Equipment, Net (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Notes Tables | |
Property, Plant and Equipment [Table Text Block] | Life December 31, (in years) 2020 2019 Medical equipment 5 $ 3,111 $ 2,933 Rental program equipment 5 1,812 1,619 Computer equipment 3 242 243 Leasehold Improvements 3 122 122 Furniture and fixtures 7 386 385 Software 3 25 25 5,698 5,327 Less: Accumulated depreciation and amortization (2,939 ) (2,281 ) Property and equipment, net $ 2,759 $ 3,046 |
Note 6 - Accrued Liabilities (T
Note 6 - Accrued Liabilities (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Notes Tables | |
Schedule of Accrued Liabilities [Table Text Block] | December 31, December 31, 2020 2019 Accrued bonuses $ 744 $ 726 Accrued payroll and other related expenses 473 839 Deferred revenue - subscription rental program 345 662 Accrued professional fees 290 592 Current operating lease liabilities 132 268 Accrued inventory 87 474 Accrued sales commission 37 281 Customer contracts liabilities 17 108 Customer advances 14 53 Accrued interest 9 440 Other accruals 268 255 Total accrued liabilities $ 2,416 $ 4,698 |
Note 7 - Note Payable (Tables)
Note 7 - Note Payable (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
The 2017 Loan Agreement [Member] | |
Notes Tables | |
Schedule of Debt [Table Text Block] | Year Ending December 31, 2021 $ - 2022 - 2023 5,992 Total payments 5,992 Less: Amount representing interest (1,465 ) Present value of obligations 4,527 Less: Unamortized debt discount (9 ) Note payable, noncurrent portion $ 4,518 |
Note 8 - Paycheck Protection _2
Note 8 - Paycheck Protection Program Loan (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Notes Tables | |
Schedule of Maturities of Long-term Debt [Table Text Block] | Year Ending December 31, 2021 $ 938 2022 426 Total payments 1,364 Less: Amount representing interest (20 ) Present value of obligations 1,344 Paycheck Protection Program loan,current portion 918 Paycheck Protection Program loan, noncurrent portion $ 425 |
Note 9 - Leases (Tables)
Note 9 - Leases (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Notes Tables | |
Lessee, Lease Assets and Liabilities [Table Text Block] | December 31, December 31, 2020 2019 Assets: Operating lease right-of-use assets $ 130 $ 395 Liabilities: Current operating lease liabilities $ 132 $ 268 Noncurrent operating lease liabilities - 132 $ 132 $ 400 |
Lessee, Operating Lease, Liability, Maturity [Table Text Block] | Year Ending December 31, 2021 $ 137 Total lease payments 137 Less: Amount representing interest (5 ) Present value of lease liabilities $ 132 |
Lessor, Operating Lease, Payment to be Received, Fiscal Year Maturity [Table Text Block] | Year Ending December 31, 2021 $ 345 Thereafter - Total $ 345 |
Note 12 - Common Stock (Tables)
Note 12 - Common Stock (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Notes Tables | |
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] | Number of Shares Outstanding Exercisable Expiration Exercise Under Issuance Date for Date Price Warrants February 2015 Common Shares February 17, 2025 $ 4,000.00 79 March 2015 Common Shares March 26, 2025 $ 2,720.00 2 May 2015 Common Shares May 12, 2025 $ 4,240.00 37 December 2015 Common Shares December 16, 2025 $ 5,600.00 31 April 2016 Common Shares April 1, 2026 $ 6,080.00 25 May 2016 Common Shares May 11, 2021 $ 7,740.00 6 June 2016 Common Shares June 20, 2026 $ 4,980.00 101 May 2017 Common Shares May 25, 2027 $ 9,500.00 223 November 2019 Common Shares November 26, 2024 $ 6.10 325,632 November 2019 Common Shares November 26, 2024 $ 18.36 989,379 April 2020 Common Shares April 21, 2025 $ 6.37 413,210 1,728,725 Number of Shares Outstanding Exercisable Expiration Exercise Under Issuance Date for Date Price Warrants February 2015 Common Shares February 17, 2025 $ 4,000.00 79 March 2015 Common Shares March 26, 2025 $ 2,720.00 2 May 2015 Common Shares May 12, 2025 $ 4,240.00 37 May 2015 Common Shares May 17, 2020 $ 4,240.00 22 December 2015 Common Shares December 16, 2025 $ 5,600.00 31 April 2016 Common Shares April 1, 2026 $ 6,080.00 25 May 2016 Common Shares May 11, 2021 $ 7,740.00 6 June 2016 Common Shares June 20, 2026 $ 4,980.00 101 May 2017 Common Shares May 25, 2027 $ 9,500.00 223 November 2019 Common Shares November 26, 2020 $ 18.36 989,379 November 2019 Common Shares November 26, 2024 $ 15.50 741,940 November 2019 Common Shares November 26, 2024 $ 15.50 741,940 2,473,785 |
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] | Immediately Immediately before Modification After Modification Exercise price $ 15.50 $ 6.10 Common stock price $ 6.30 $ 6.30 Expected term (in years) 2.8 2.8 Average volatility 97 % 97 % Risk-free interest rate 0.27 % 0.27 % Dividend yield 0 % 0 % |
Note 13 - Summary of Stock Op_2
Note 13 - Summary of Stock Options (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Notes Tables | |
Share-based Payment Arrangement, Option, Activity [Table Text Block] | Year Ended December 31, 2020 Weighted Weighted Average Number Average Remaining Aggregate of Exercise Contractual Intrinsic Shares Price Term (years) Value Options outstanding, January 1, 2019 4,098 $ 4,567.36 7.4 $ - Options granted 1,006,602 $ 11.42 Options exercised - Options canceled (1,867 ) $ 4,040.64 Options outstanding, December 31, 2019 1,008,833 $ 22.47 9.9 $ 3,928,715 Options granted 146,700 $ 6.36 Options exercised - Options canceled (169,134 ) $ 28.45 Options outstanding, December 31, 2020 986,399 $ 19.10 8.9 $ 675 Vested and exercisable and expected to vest, December 31, 2020 923,646 $ 19.77 8.9 $ 598 Vested and exercisable, December 31, 2020 245,445 $ 45.09 8.6 $ - |
Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block] | Weighted Number Weighted Average Number Weighted Outstanding Average Remaining Exercisable Average Range of as of Exercise Contractual as of Exercise Exercise Prices December 31, 2020 Price Term (Years) December 31, 2020 Price $4.45 - $8.91 967,288 $ 8.32 8.9 238,900 $ 8.69 $10.90 - $13.60 15,500 $ 12.64 9.2 3,750 $ 13.60 $380.00 - $580.00 125 $ 552.00 8.4 113 $ 567.61 $1,000.00 - $1,970.00 1,954 $ 1,426.46 7.6 1,334 $ 1,437.21 $2,020.00 - $2,830.00 74 $ 2,501.22 7.0 53 $ 2,520.19 $3,110.00 - $3,580.00 189 $ 3,439.26 7.6 156 $ 3,455.90 $4,360.00 - $4,970.00 619 $ 4,549.77 6.2 510 $ 4,554.04 $5,010.00 - $5,670.00 300 $ 5,366.00 6.2 285 $ 5,356.84 $6,000.00 - $6,000.00 138 $ 6,000.00 5.0 138 $ 6,000.00 $7,140.00 - $7,920.00 200 $ 7,679.20 4.1 194 $ 7,676.29 $9,920.00 - $9,920.00 12 $ 9,920.00 2.1 12 $ 9,920.00 Total: 986,399 $ 19.10 8.9 245,445 $ 45.09 |
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] | Year Ended December 31, 2020 2019 Expected term (in years) 5 6 Average volatility 82 % 70 % Risk-free interest rate 0.37 % 1.62 % Dividend yield - - |
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] | Year Ended December 31, 2020 2019 Cost of revenue $ 208 $ 135 Research and development 325 192 Selling, general and administrative 2,118 2,073 Total $ 2,651 $ 2,400 |
Note 14 - Income Taxes (Tables)
Note 14 - Income Taxes (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Notes Tables | |
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] | Year Ended December 31, 2020 2019 Income tax benefit at statutory rate (21 )% (21 )% State income taxes, net of federal benefit (3 )% (4 )% Change in valuation allowance 20 % (39 )% Debt restructuring 0 % 6 % Limitation on net operating loss and credit carryovers 0 % 56 % Other 4 % 2 % Effective tax rate 0 % 0 % |
Schedule of Deferred Tax Assets and Liabilities [Table Text Block] | December 31, 2020 2019 Deferred tax assets: Net operating loss carryforwards $ 20,891 $ 16,688 Capitalized start up costs 2,866 3,225 Research and development credits 631 527 Accruals and reserves 773 532 Fixed assets and depreciation 291 128 Total deferred tax assets 25,452 21,100 Deferred tax liabilities: Valuation allowance (25,452 ) (21,100 ) Net deferred tax assets $ - $ - |
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block] | Year Ended December 31, 2020 2019 Balance at the beginning of the year $ 223 $ 450 Additions (deletions) based upon tax positions related to the current year 22 (227 ) Balance at the end of the year $ 245 $ 223 |
Note 16 - Segments and Geogra_2
Note 16 - Segments and Geographic Information (Tables) | 12 Months Ended |
Dec. 31, 2020 | |
Notes Tables | |
Long-lived Assets by Geographic Areas [Table Text Block] | December 31, 2020 2019 United States $ 2,622 $ 2,818 Asia Pacific 76 64 Canada 54 142 Europe 7 22 Total $ 2,759 $ 3,046 |
Note 1 - The Company and Basi_2
Note 1 - The Company and Basis of Presentation (Details Textual) - USD ($) | Jan. 19, 2021 | Jun. 09, 2020 | Jun. 08, 2020 | Apr. 20, 2020 | Apr. 16, 2020 | Nov. 12, 2019 | Sep. 30, 2020 | Aug. 31, 2020 | Jun. 30, 2020 | May 31, 2020 | Feb. 29, 2020 | Nov. 30, 2019 | Nov. 30, 2019 | Dec. 31, 2021 | Dec. 31, 2020 | Dec. 31, 2019 | Jan. 31, 2021 | Jan. 18, 2021 | Dec. 16, 2020 | Apr. 15, 2020 |
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 2,473,785 | |||||||||||||||||||
Preferred Stock, Shares Authorized (in shares) | 10,000,000 | 10,000,000 | ||||||||||||||||||
Proceeds from Warrant Exercises | $ 8,407,000 | |||||||||||||||||||
Payments of Warrant Issuance Costs | $ 334,000 | 334,000 | ||||||||||||||||||
Debt Conversion, Converted Instrument, Amount | 35,529,000 | |||||||||||||||||||
Retained Earnings (Accumulated Deficit), Ending Balance | (219,826,000) | (197,911,000) | ||||||||||||||||||
Cash and Cash Equivalents, at Carrying Value, Ending Balance | 6,523,000 | 13,308,000 | ||||||||||||||||||
Working Capital | 8,628,000 | |||||||||||||||||||
Net Cash Provided by (Used in) Operating Activities, Total | (15,234,000) | (31,236,000) | ||||||||||||||||||
Net Cash Provided by (Used in) Financing Activities, Total | $ 9,230,000 | $ 16,108,000 | ||||||||||||||||||
Series B Convertible Preferred Stock Into Common Stock [Member] | Minimum [Member] | ||||||||||||||||||||
Conversion of Stock, Conversion Rate (in dollars per share) | $ 15.30 | |||||||||||||||||||
Series B Convertible Preferred Stock Into Common Stock [Member] | Maximum [Member] | ||||||||||||||||||||
Conversion of Stock, Conversion Rate (in dollars per share) | $ 18.36 | |||||||||||||||||||
Conversion of Term Loan with CRG Into Stock and Warrants [Member] | ||||||||||||||||||||
Debt Conversion, Original Debt, Amount | $ 28,981,000 | |||||||||||||||||||
Debt Conversion, Converted Instrument, Amount | $ 31,300,000 | |||||||||||||||||||
Conversion of Term Loan with CRG Into Series B Convertible Preferred Stock [Member] | ||||||||||||||||||||
Debt Conversion, Converted Instrument, Shares Issued (in shares) | 31,300 | |||||||||||||||||||
Series A and Series B Warrants [Member] | ||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 15.50 | $ 6.10 | ||||||||||||||||||
Proceeds from Warrant Exercises | $ 3,089,000 | |||||||||||||||||||
Series A Warrants [Member] | ||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | 1 | ||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 15.50 | $ 15.50 | $ 18.36 | |||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 1 year | 1 year | ||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 741,939 | 741,939 | 989,379 | |||||||||||||||||
Stock Issued During Period, Shares, Warrant Exercises (in shares) | 482,059 | 111,704 | 2,761 | 410 | 102,626 | |||||||||||||||
Proceeds from Warrant Exercises | $ 681,000 | $ 17,000 | $ 2,000 | $ 1,591,000 | ||||||||||||||||
Class of Warrant or Right, Outstanding (in shares) | 0 | |||||||||||||||||||
Series B Warrants [Member] | ||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | 1 | ||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 15.50 | $ 15.50 | $ 15.50 | |||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | 5 years | ||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 741,939 | 741,939 | 325,632 | 741,940 | ||||||||||||||||
Stock Issued During Period, Shares, Warrant Exercises (in shares) | 24,279 | 1,500 | 380,913 | 5,070 | 4,548 | |||||||||||||||
Proceeds from Warrant Exercises | $ 9,000 | $ 2,324,000 | $ 31,000 | $ 70,000 | ||||||||||||||||
Class of Warrant or Right, Outstanding (in shares) | 325,632 | |||||||||||||||||||
Series A-2 Warrants [Member] | ||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 482,059 | 392,830 | ||||||||||||||||||
Stock Issued During Period, Shares, Warrant Exercises (in shares) | 89,230 | 392,830 | ||||||||||||||||||
Proceeds from Warrant Exercises | $ 568,000 | |||||||||||||||||||
Series B-2 Warrants [Member] | ||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 24,279 | 20,380 | ||||||||||||||||||
Stock Issued During Period, Shares, Warrant Exercises (in shares) | 3,899 | 20,380 | ||||||||||||||||||
Proceeds from Warrant Exercises | $ 25,000 | |||||||||||||||||||
Series A-2 and Series B-2 Warrants [Member] | ||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 6.371 | |||||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | |||||||||||||||||||
Class of Warrant or Right, Outstanding (in shares) | 1,838,000 | |||||||||||||||||||
Warrants Issued Upon Conversion of Term Loan with CRG [Member] | ||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 15.50 | |||||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | |||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 989,379 | 741,940 | ||||||||||||||||||
Class of Warrants and Rights Outstanding, Exercise Price Percentage of Conversion Rate | 120.00% | |||||||||||||||||||
Class A Units [Member] | Series A Warrants [Member] | ||||||||||||||||||||
Warrants Per Unit (in shares) | 1 | 1 | ||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | 1 | ||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 15.50 | $ 15.50 | ||||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 1 year | 1 year | ||||||||||||||||||
Class A Units [Member] | Series B Warrants [Member] | ||||||||||||||||||||
Warrants Per Unit (in shares) | 1 | 1 | ||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | 1 | ||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 15.50 | $ 15.50 | ||||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | 5 years | ||||||||||||||||||
Class B Units [Member] | Series A Warrants [Member] | ||||||||||||||||||||
Warrants Per Unit (in shares) | 1 | 1 | ||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | 1 | ||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 15.50 | $ 15.50 | ||||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 1 year | 1 year | ||||||||||||||||||
Class B Units [Member] | Series B Warrants [Member] | ||||||||||||||||||||
Warrants Per Unit (in shares) | 1 | 1 | ||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | 1 | ||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 15.50 | $ 15.50 | ||||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | 5 years | ||||||||||||||||||
Common Stock [Member] | ||||||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 52,500 | |||||||||||||||||||
Common Stock [Member] | Series A and Series B Warrants [Member] | ||||||||||||||||||||
Stock Issued During Period, Shares, Warrant Exercises (in shares) | 1,115,863 | |||||||||||||||||||
Common Stock [Member] | Series A-2 and Series B-2 Warrants [Member] | ||||||||||||||||||||
Stock Issued During Period, Shares, Warrant Exercises (in shares) | 93,129 | |||||||||||||||||||
Series A Preferred Stock [Member] | ||||||||||||||||||||
Convertible Preferred Stock, Shares Issued upon Conversion (in shares) | 1 | 1 | 1 | 1 | ||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 547,345 | |||||||||||||||||||
Preferred Stock, Shares Outstanding, Ending Balance (in shares) | 0 | 185,218 | 0 | |||||||||||||||||
Preferred Stock, Shares Authorized (in shares) | 547,345 | 547,345 | ||||||||||||||||||
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ 0.0001 | $ 0.0001 | $ 0.0001 | |||||||||||||||||
Subsequent Event [Member] | Series A and Series B Warrants [Member] | ||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 3.40 | $ 6.10 | ||||||||||||||||||
Subsequent Event [Member] | Series A-2 and Series B-2 Warrants [Member] | ||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | |||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 3.40 | $ 6.371 | ||||||||||||||||||
Subsequent Event [Member] | Class A Units [Member] | Warrants Issued in Connection with Class A Units [Member] | ||||||||||||||||||||
Warrants Per Unit (in shares) | 1 | |||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | |||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 3.40 | |||||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | |||||||||||||||||||
Subsequent Event [Member] | Class B Units [Member] | Warrants Issued in Connection with Class B Units [Member] | ||||||||||||||||||||
Warrants Per Unit (in shares) | 1 | |||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | |||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 3.40 | |||||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | |||||||||||||||||||
Subsequent Event [Member] | Series C Preferred Stock [Member] | ||||||||||||||||||||
Preferred Stock, Shares Outstanding, Ending Balance (in shares) | 0 | |||||||||||||||||||
January 2021 Offering [Member] | Subsequent Event [Member] | ||||||||||||||||||||
Proceeds from Issuance or Sale of Equity, Total | $ 27,600,000 | |||||||||||||||||||
Shares Issued, Price Per Share (in dollars per share) | $ 3.40 | |||||||||||||||||||
Proceeds from Issuance or Sale of Equity, Net of Issuance Costs | $ 25,223,000 | |||||||||||||||||||
January 2021 Offering [Member] | Subsequent Event [Member] | Class A Units [Member] | ||||||||||||||||||||
Units Issued, Shares (in shares) | 4,607,940 | |||||||||||||||||||
Shares Issued, Price Per Share (in dollars per share) | $ 3.40 | |||||||||||||||||||
Common Shares Per Unit (in shares) | 1 | |||||||||||||||||||
January 2021 Offering [Member] | Subsequent Event [Member] | Class B Units [Member] | ||||||||||||||||||||
Units Issued, Shares (in shares) | 2,450,880 | |||||||||||||||||||
Shares Issued, Price Per Share (in dollars per share) | $ 3.40 | |||||||||||||||||||
Series C Convertible Preferred Stock Per Unit (in shares) | 1 | |||||||||||||||||||
January 2021 Offering [Member] | Subsequent Event [Member] | Series C Preferred Stock [Member] | ||||||||||||||||||||
Convertible Preferred Stock, Shares Issued upon Conversion (in shares) | 1 | |||||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 2,450,880 | |||||||||||||||||||
Over-Allotment Option [Member] | Subsequent Event [Member] | ||||||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 1,058,820 | |||||||||||||||||||
Over-Allotment Option [Member] | Subsequent Event [Member] | Warrants Issued in Connection with January 2021 Offering [Member] | ||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 1,058,820 | |||||||||||||||||||
Purchase Agreement with LPC [Member] | ||||||||||||||||||||
Shares Issued, Price Per Share (in dollars per share) | $ 6.50 | |||||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 52,500 | |||||||||||||||||||
Maximum Amount of Shares Issuable | $ 10,000,000 | |||||||||||||||||||
Stock Purchase Agreement Duration Period (Month) | 2 years 180 days | |||||||||||||||||||
Maximum Number of Shares Issuable on Any Business Day Selected by The Company (in shares) | 25,000 | |||||||||||||||||||
Maximum Number of Shares Issuable on Any Business Day Selected by The Company in Certain Circumstances (in shares) | 50,000 | |||||||||||||||||||
Purchase Agreement with LPC [Member] | Forecast [Member] | ||||||||||||||||||||
Proceeds from Issuance or Sale of Equity, Total | $ 9,700,000 | |||||||||||||||||||
November 2019 Offering [Member] | ||||||||||||||||||||
Proceeds from Issuance or Sale of Equity, Total | $ 11,500,000 | |||||||||||||||||||
Shares Issued, Price Per Share (in dollars per share) | $ 15.50 | $ 15.50 | ||||||||||||||||||
Common Shares Per Unit (in shares) | 1 | 1 | ||||||||||||||||||
Proceeds From Issuance of Common Stock, Net | $ 9,922,000 | |||||||||||||||||||
November 2019 Offering [Member] | Class A Units [Member] | ||||||||||||||||||||
Shares Issued, Price Per Share (in dollars per share) | $ 15.50 | $ 15.50 | ||||||||||||||||||
Common Shares Per Unit (in shares) | 1 | 1 | ||||||||||||||||||
November 2019 Offering [Member] | Class B Units [Member] | ||||||||||||||||||||
Shares Issued, Price Per Share (in dollars per share) | $ 15.50 | $ 15.50 | ||||||||||||||||||
Series A Convertible Preferred Stock Per Unit (in shares) | 1 | 1 | ||||||||||||||||||
November 2019 Offering [Member] | Common Stock [Member] | ||||||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 194,595 | 194,595 | 194,595 | |||||||||||||||||
November 2019 Offering [Member] | Series A Preferred Stock [Member] | ||||||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 547,345 | 547,341 | ||||||||||||||||||
November 2019 Offering [Member] | Series A Preferred Stock [Member] | Class B Units [Member] | ||||||||||||||||||||
Convertible Preferred Stock, Shares Issued upon Conversion (in shares) | 1 | 1 |
Note 2 - Summary of Significa_3
Note 2 - Summary of Significant Accounting Policies (Details Textual) | Dec. 01, 2020USD ($)shares | Sep. 18, 2019USD ($) | Dec. 31, 2020USD ($)$ / sharesshares | Dec. 31, 2019USD ($)$ / sharesshares | Dec. 16, 2020shares | Nov. 30, 2019shares | Jan. 01, 2019USD ($) |
Common Stock, Shares Authorized (in shares) | shares | 75,000,000 | 75,000,000 | |||||
Reverse Stock Split, Rounding Adjustment (in shares) | shares | 5,931 | ||||||
Payments for Fractional Shares of Reverse Stock Split | $ 0 | $ 6,000 | |||||
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares | $ 0.0001 | $ 0.0001 | |||||
Operating Lease, Right-of-Use Asset | $ 130,000 | $ 395,000 | $ 629,000 | ||||
Number of Financial Institutions | 1 | ||||||
Accounts Receivable, Allowance for Credit Loss, Ending Balance | $ 124,000 | 407,000 | |||||
Accounts Receivable, Allowance for Credit Loss, Writeoff | 736,000 | 905,000 | |||||
Inventory, Finished Goods, Net of Reserves | 2,818,000 | 4,051,000 | |||||
Inventory, Raw Materials, Net of Reserves | 436,000 | 810,000 | |||||
Revenue from Contract with Customer, Excluding Assessed Tax, Total | 5,479,000 | 6,567,000 | |||||
Deferred Income | 345,000 | 662,000 | |||||
Contract with Customer, Asset, after Allowance for Credit Loss, Total | 0 | 0 | |||||
Contract with Customer, Liability, Total | 17,000 | 108,000 | |||||
Capitalized Contract Cost, Net, Total | 132,000 | 486,000 | |||||
Capitalized Contract Cost, Amortization | 417,000 | 143,000 | |||||
Capitalized Contract Cost, Impairment Loss | 0 | ||||||
Equity Method Investment, Other than Temporary Impairment | $ 0 | $ 0 | |||||
Series A Preferred Stock [Member] | |||||||
Convertible Preferred Stock, Shares Issued upon Conversion (in shares) | shares | 1 | 1 | 1 | ||||
Preferred Stock, Shares Outstanding, Ending Balance (in shares) | shares | 0 | 185,218 | 0 | ||||
Series B Preferred Stock [Member] | |||||||
Convertible Preferred Stock, Shares Issued upon Conversion (in shares) | shares | 2,341,111 | 270,458 | |||||
Preferred Stock, Shares Outstanding, Ending Balance (in shares) | shares | 35,819 | 31,678 | |||||
Conversion of Stock Exchange Ratio | 65.36 | ||||||
Preferred Stock, Liquidation Preference Per Share (in dollars per share) | $ / shares | $ 1,000 | ||||||
Conversion of Stock, Conversion Rate (in dollars per share) | $ / shares | $ 15.30 | ||||||
Rental [Member] | |||||||
Revenue from Contract with Customer, Excluding Assessed Tax, Total | $ 1,337,000 | $ 530,000 | |||||
Rental Program Equipment [Member] | |||||||
Revenue from Contract with Customer, Excluding Assessed Tax, Total | 594,000 | ||||||
Marketing Programs [Member] | |||||||
Contract with Customer, Liability, Total | $ 17,000 | $ 108,000 | |||||
Minimum [Member] | |||||||
Property, Plant and Equipment, Useful Life (Year) | 3 years | ||||||
Warranty Period (Year) | 1 year | ||||||
Maximum [Member] | |||||||
Property, Plant and Equipment, Useful Life (Year) | 7 years | ||||||
Warranty Period (Year) | 3 years | ||||||
Viveve Systems [Member] | |||||||
Property, Plant and Equipment, Useful Life (Year) | 5 years | ||||||
Medical Equipment, Sales Demos [Member] | |||||||
Property, Plant and Equipment, Useful Life (Year) | 5 years | ||||||
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | |||||||
Concentration Risk, Number of Customers | 1 | 1 | |||||
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | One Customer [Member] | |||||||
Concentration Risk, Percentage | 36.00% | 16.00% | |||||
Customer Concentration Risk [Member] | Accounts Receivable [Member] | |||||||
Concentration Risk, Number of Customers | 1 | 2 | |||||
Customer Concentration Risk [Member] | Accounts Receivable [Member] | One Customer [Member] | |||||||
Concentration Risk, Percentage | 37.00% | ||||||
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Two Customers [Member] | |||||||
Concentration Risk, Percentage | 49.00% | ||||||
Accrued Liabilities and Other Noncurrent Liabilities [Member] | |||||||
Operating Lease, Liability, Total | $ 132,000 | $ 400,000 | $ 629,000 | ||||
Reverse Stock Split [Member] | |||||||
Stockholders' Equity Note, Stock Split, Conversion Ratio | 10 | 100 |
Note 2 - Summary of Significa_4
Note 2 - Summary of Significant Accounting Policies - Cumulative Effect of Adjustments for New Accounting Pronouncements on Consolidated Balance Sheet (Details) - USD ($) $ in Thousands | Dec. 31, 2020 | Dec. 31, 2019 | Jan. 01, 2019 | Dec. 31, 2018 | |
Other assets | $ 195 | $ 526 | $ 800 | $ 171 | |
Total assets | 16,630 | 26,977 | 47,463 | 46,834 | |
Total accrued liabilities | 2,416 | 4,698 | 6,996 | 6,766 | |
Total current liabilities | 4,215 | 6,306 | 10,990 | 10,760 | |
Other noncurrent liabilities | 498 | 167 | 1,033 | 634 | |
Total liabilities | 9,656 | 10,456 | 42,551 | 41,922 | |
Total liabilities and stockholders' equity | $ 16,630 | $ 26,977 | 47,463 | $ 46,834 | |
Accounting Standards Update 2016-02 [Member] | |||||
Other assets | [1] | 629 | |||
Total assets | [1] | 629 | |||
Total accrued liabilities | [2] | 230 | |||
Total current liabilities | [2] | 230 | |||
Other noncurrent liabilities | [2] | 399 | |||
Total liabilities | [2] | 629 | |||
Total liabilities and stockholders' equity | [2] | $ 629 | |||
[1] | Represents capitalization of operating lease right-of-use assets and reclassification of deferred rent. | ||||
[2] | Represents recognition of operating lease liabilities. |
Note 2 - Summary of Significa_5
Note 2 - Summary of Significant Accounting Policies - Customer Contract Liabilities (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Customer contract liabilities | $ 17,000 | $ 108,000 |
Change in customer contract liabilities | (91,000) | |
Marketing Programs [Member] | ||
Customer contract liabilities | 17,000 | $ 108,000 |
Change in customer contract liabilities | $ (91,000) |
Note 2 - Summary of Significa_6
Note 2 - Summary of Significant Accounting Policies - Revenue From Unaffiliated Customers by Geographic Area (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Revenue | $ 5,479 | $ 6,567 |
Asia Pacific [Member] | ||
Revenue | 2,732 | 2,349 |
North America [Member] | ||
Revenue | 2,537 | 3,672 |
CANADA | ||
Revenue | 110 | 277 |
Europe And Middle East [Member] | ||
Revenue | 86 | 254 |
Latin America [Member] | ||
Revenue | $ 14 | $ 15 |
Note 2 - Summary of Significa_7
Note 2 - Summary of Significant Accounting Policies - Antidilutive Securities (Details) - shares | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | ||
Series A Convertible Preferred Stock [Member] | |||
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares) | [1] | 185,218 | |
Series B Convertible Preferred Stock [Member] | |||
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares) | 2,341,111 | [2] | 2,070,458 |
Common Stock Warrants [Member] | |||
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares) | 1,728,725 | 2,473,785 | |
Share-based Payment Arrangement, Option [Member] | |||
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares) | 986,399 | 1,008,833 | |
Restricted Stock [Member] | |||
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares) | 394 | 277 | |
[1] | Each share of Series A convertible preferred stock was convertible at any time at the holder's option into one share of common stock. In December 2020, the Company filed a Certificate of Elimination with the Delaware Secretary of State with respect to the authorized shares of Series A convertible preferred stock. As of December 31, 2020, all Series A convertible preferred stock had been converted into common stock and there were no remaining shares outstanding. | ||
[2] | As of December 31, 2020 and 2019, a total of 35,819 and 31,678 shares of Series B convertible preferred stock were outstanding and convertible into 2,341,111 and 2,70,458 shares of common stock, respectively. Each share of Series B convertible preferred stock is convertible at the holder's option into shares of common stock at a conversion ratio of 1-for-65.36 per share determined by dividing the Series B liquidation amount of $1,000 per share by the Series B conversion price of $15.30 per share. However, under the terms of the Series B Preferred Stock and Warrant Purchase Agreement, as amended, CRG will not convert the Series B preferred stock or exercise the CRG warrants until the Company's stockholders act to authorize additional number of shares of common stock sufficient to cover the conversion shares. |
Note 4 - Property and Equipme_3
Note 4 - Property and Equipment, Net (Details Textual) - USD ($) | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Depreciation, Total | $ 1,295,000 | $ 1,177,000 |
Note 4 - Property and Equipme_4
Note 4 - Property and Equipment, Net - Equipment, Furniture, and Leasehold Improvements (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Property and equipment, gross | $ 5,698 | $ 5,327 |
Less: Accumulated depreciation and amortization | (2,939) | (2,281) |
Property and equipment, net | $ 2,759 | 3,046 |
Equipment [Member] | ||
Property, Plant and Equipment, Useful Life (Year) | 5 years | |
Property and equipment, gross | $ 3,111 | 2,933 |
Rental Program Equipment [Member] | ||
Property, Plant and Equipment, Useful Life (Year) | 5 years | |
Property and equipment, gross | $ 1,812 | 1,619 |
Computer Equipment [Member] | ||
Property, Plant and Equipment, Useful Life (Year) | 3 years | |
Property and equipment, gross | $ 242 | 243 |
Leasehold Improvements [Member] | ||
Property, Plant and Equipment, Useful Life (Year) | 3 years | |
Property and equipment, gross | $ 122 | 122 |
Furniture and Fixtures [Member] | ||
Property, Plant and Equipment, Useful Life (Year) | 7 years | |
Property and equipment, gross | $ 386 | 385 |
Software [Member] | ||
Property, Plant and Equipment, Useful Life (Year) | 3 years | |
Property and equipment, gross | $ 25 | $ 25 |
Note 5 - Investment in Limite_2
Note 5 - Investment in Limited Liability Company (Details Textual) | Aug. 08, 2017USD ($) | Dec. 31, 2020USD ($) | Dec. 31, 2019USD ($) |
Income (Loss) from Equity Method Investments, Total | $ (383,000) | $ (627,000) | |
InControl Medical [Member] | |||
Equity Method Investment, Ownership Percentage | 7.00% | ||
Income (Loss) from Equity Method Investments, Total | $ 383,000 | $ 627,000 | |
InControl Medical [Member] | Membership Unit Subscription Agreement [Member] | |||
Unrecorded Unconditional Purchase Obligation, Period Quantity Purchased | 485 | 300 | |
Unrecorded Unconditional Purchase Obligation, Purchases | $ 51,000 | $ 26,000 | |
Payments for Purchase of Products | 52,000 | 27,000 | |
Accounts Payable, Related Parties, Current | $ 0 | $ 0 | |
Payments to Acquire Equity Method Investments | $ 2,500,000 |
Note 6 - Accrued Liabilities -
Note 6 - Accrued Liabilities - Accrued Liabilities (Details) - USD ($) $ in Thousands | Dec. 31, 2020 | Dec. 31, 2019 | Jan. 01, 2019 | Dec. 31, 2018 |
Accrued bonuses | $ 744 | $ 726 | ||
Accrued payroll and other related expenses | 473 | 839 | ||
Deferred revenue - subscription rental program | 345 | 662 | ||
Accrued professional fees | 290 | 592 | ||
Accrued inventory | 87 | 474 | ||
Accrued sales commission | 37 | 281 | ||
Accrued interest | 9 | 440 | ||
Other accruals | 268 | 255 | ||
Total accrued liabilities | 2,416 | 4,698 | $ 6,996 | $ 6,766 |
Customer Contracts Liabilites [Member] | ||||
Contract with customer, liability | 17 | 108 | ||
Customer Advances [Member] | ||||
Contract with customer, liability | 14 | 53 | ||
Accrued Liabilities [Member] | ||||
Current operating lease liabilities | $ 132 | $ 268 |
Note 7 - Note Payable (Details
Note 7 - Note Payable (Details Textual) - USD ($) | Nov. 12, 2019 | Dec. 29, 2017 | May 22, 2017 | Dec. 31, 2020 | Dec. 31, 2019 | Nov. 26, 2019 |
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 2,473,785 | |||||
Debt Conversion, Converted Instrument, Amount | $ 35,529,000 | |||||
Notes Payable, Noncurrent, Total | 4,518,000 | 3,983,000 | ||||
Warrants and Rights Outstanding | 3,502,000 | |||||
Gains (Losses) on Restructuring of Debt | $ (6,705,000) | |||||
Series B Preferred Stock [Member] | ||||||
Conversion of Stock, Conversion Rate (in dollars per share) | $ 15.30 | |||||
Preferred Stock, Fair Value, Per Share (in dollars per share) | $ 1,023.23 | |||||
Convertible Preferred Stock, Fair Value | $ 32,027,000 | |||||
Series B Convertible Preferred Stock Into Common Stock [Member] | Minimum [Member] | ||||||
Conversion of Stock, Conversion Rate (in dollars per share) | $ 15.30 | |||||
Series B Convertible Preferred Stock Into Common Stock [Member] | Maximum [Member] | ||||||
Conversion of Stock, Conversion Rate (in dollars per share) | $ 18.36 | |||||
Conversion of Term Loan with CRG Into Stock and Warrants [Member] | ||||||
Debt Conversion, Original Debt, Amount | $ 28,981,000 | |||||
Debt Conversion, Converted Instrument, Amount | $ 31,300,000 | |||||
Conversion of Term Loan with CRG Into Series B Convertible Preferred Stock [Member] | ||||||
Debt Conversion, Converted Instrument, Shares Issued (in shares) | 31,300 | |||||
May 2017 Issuance Related to 2017 Loan Agreement [Member] | ||||||
Warrants and Rights Outstanding, Term (Year) | 10 years | |||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 223 | 223 | ||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 9,500 | $ 9,500 | ||||
Warrants and Rights Outstanding | $ 940,000 | |||||
Warrants Issued Upon Conversion of Term Loan with CRG [Member] | ||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | |||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 989,379 | 741,940 | ||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 15.50 | |||||
Class of Warrants and Rights Outstanding, Exercise Price Percentage of Conversion Rate | 120.00% | |||||
Warrants and Rights Outstanding | $ 3,502,000 | |||||
The 2017 Loan Agreement [Member] | ||||||
Notes Payable, Noncurrent, Total | $ 4,518,000 | |||||
The 2017 Loan Agreement [Member] | CRG LP [Member] | ||||||
Debt Instrument, Face Amount | 20,000,000 | |||||
Debt Agreement, Covenant, Additional Funding | 10,000,000 | |||||
Debt Agreement, Maximum Borrowing Capacity | $ 30,000,000 | |||||
Proceeds from Lines of Credit, Total | $ 10,000,000 | |||||
Debt Instrument, Term (Year) | 6 years | |||||
Debt instrument, Interest Only Payment, Period (Year) | 4 years | |||||
Debt Instrument, Interest Rate, Stated Percentage | 12.50% | |||||
Debt Instrument, Interest Rate, Stated Percentage Deferred During Interest-only Period | 4.00% | |||||
Paid-in-Kind Interest | 532,000 | $ 1,226,000 | ||||
Debt Instrument, Prepayment Fee, Percentage | 5.00% | |||||
Debt Instrument, Back-end Facility Fee Percentage of Principal | 25.00% | 5.00% | ||||
Notes Payable, Noncurrent, Total | $ 4,518,000 | $ 3,983,000 |
Note 7 - Note Payable - Summary
Note 7 - Note Payable - Summary of Note Payable (Details) - USD ($) | Dec. 31, 2020 | Dec. 31, 2019 |
Less: Unamortized debt discount | $ (9,000) | |
Note payable, noncurrent portion | 4,518,000 | $ 3,983,000 |
The 2017 Loan Agreement [Member] | ||
2021 | ||
2022 | ||
2023 | 5,992,000 | |
Total payments | 5,992,000 | |
Less: Amount representing interest | (1,465,000) | |
Present value of obligations | 4,527,000 | |
Less: Unamortized debt discount | (9,000) | |
Note payable, noncurrent portion | $ 4,518,000 |
Note 8 - Paycheck Protection _3
Note 8 - Paycheck Protection Program Loan (Details Textual) - USD ($) | Apr. 24, 2020 | Dec. 31, 2020 | Dec. 31, 2019 |
Proceeds from Issuance of Unsecured Debt | $ 1,343,000 | ||
Paycheck Protection Program CARES Act [Member] | |||
Proceeds from Issuance of Unsecured Debt | $ 1,343,000 |
Note 8 - Paycheck Protection _4
Note 8 - Paycheck Protection Program Loan - Summary of Paycheck Protection Program Loan (Details) - Paycheck Protection Program CARES Act [Member] $ in Thousands | Dec. 31, 2020USD ($) |
2021 | $ 938 |
2022 | 426 |
Total payments | 1,364 |
Less: Amount representing interest | (20) |
Present value of obligations | 1,344 |
Paycheck Protection Program loan,current portion | 918 |
Paycheck Protection Program loan, noncurrent portion | $ 425 |
Note 9 - Leases (Details Textua
Note 9 - Leases (Details Textual) | 1 Months Ended | 12 Months Ended | ||
Sep. 30, 2018USD ($) | Dec. 31, 2020USD ($) | Dec. 31, 2019USD ($) | Feb. 01, 2017USD ($)ft² | |
Operating Lease, Expense | $ 300,000 | $ 301,000 | ||
Operating Lease, Weighted Average Remaining Lease Term (Month) | 150 days | |||
Operating Lease, Weighted Average Discount Rate, Percent | 12.50% | |||
Operating Lease, Property Plant and Equipment, Amount | $ 841,000 | |||
Sublease Agreement for Relocation of Headquarters [Member] | ||||
Area of Real Estate Property (Square Foot) | ft² | 12,400 | |||
Operating Leases, Monthly Rent Per Rentable Square Foot During First Year | 20.5 | |||
Operating Leases, Monthly Rent Per Rentable Square Foot During Second Year | 21.12 | |||
Operating Leases, Monthly Rent Per Rentable Square Foot During Third Year | 21.75 | |||
Security Deposit | $ 22,000 | |||
Operating Leases, Allowance for Certain Improvements | $ 88,000 | |||
Noncancelable Operating Lease Agreement for Office Equipment [Member] | ||||
Lessee, Operating Lease, Term of Contract (Month) | 3 years | |||
Operating Leases, Monthly Payment | $ 3,000 | |||
Leases of Viveve Systems [Member] | ||||
Lessor, Operating Lease, Depreciation on Leased Assets | $ 462,000 | $ 121,000 |
Note 9 - Leases - Lease Assets
Note 9 - Leases - Lease Assets and Liabilities (Details) - USD ($) | Dec. 31, 2020 | Dec. 31, 2019 | Jan. 01, 2019 |
Operating Lease, Right-of-Use Asset | $ 130,000 | $ 395,000 | $ 629,000 |
Accrued Liabilities [Member] | |||
Current operating lease liabilities | 132,000 | 268,000 | |
Other Noncurrent Liabilities [Member] | |||
Noncurrent operating lease liabilities | 132,000 | ||
Accrued Liabilities and Other Noncurrent Liabilities [Member] | |||
Operating Lease, Liability, Total | $ 132,000 | $ 400,000 | $ 629,000 |
Note 9 - Leases - Maturity of O
Note 9 - Leases - Maturity of Operating Lease Liabilities (Details) - USD ($) | Dec. 31, 2020 | Dec. 31, 2019 | Jan. 01, 2019 |
2021 | $ 137,000 | ||
Total lease payments | 137,000 | ||
Less: Amount representing interest | (5,000) | ||
Accrued Liabilities and Other Noncurrent Liabilities [Member] | |||
Present value of lease liabilities | $ 132,000 | $ 400,000 | $ 629,000 |
Note 9 - Leases - Minimum Futur
Note 9 - Leases - Minimum Future Rentals (Details) $ in Thousands | Dec. 31, 2020USD ($) |
2021 | $ 345 |
Thereafter | |
Total | $ 345 |
Note 11 - Preferred Stock (Deta
Note 11 - Preferred Stock (Details Textual) - USD ($) | Nov. 26, 2019 | Nov. 12, 2019 | Nov. 30, 2019 | Feb. 29, 2020 | Dec. 31, 2019 | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2020 | Dec. 16, 2020 |
Preferred Stock, Shares Authorized (in shares) | 10,000,000 | 10,000,000 | 10,000,000 | 10,000,000 | |||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 2,473,785 | 2,473,785 | |||||||
Warrants Issued Upon Conversion of Term Loan with CRG [Member] | |||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 989,379 | 741,940 | 741,940 | ||||||
Conversion of Term Loan with CRG Into Series B Convertible Preferred Stock [Member] | |||||||||
Debt Conversion, Converted Instrument, Shares Issued (in shares) | 31,300 | ||||||||
Series A Convertible Preferred Stock Into Common Stock [Member] | |||||||||
Conversion of Stock, Shares Converted (in shares) | 185,218 | 362,127 | |||||||
Series A Preferred Stock [Member] | |||||||||
Convertible Preferred Stock, Shares Issued upon Conversion (in shares) | 1 | 1 | 1 | 1 | 1 | ||||
Stock Issued During Period, Shares, New Issues (in shares) | 547,345 | ||||||||
Preferred Stock, Shares Outstanding, Ending Balance (in shares) | 185,218 | 0 | 185,218 | 0 | 0 | ||||
Preferred Stock, Shares Authorized (in shares) | 547,345 | 547,345 | 547,345 | ||||||
Series B Preferred Stock [Member] | |||||||||
Convertible Preferred Stock, Shares Issued upon Conversion (in shares) | 270,458 | 2,341,111 | 270,458 | 2,341,111 | |||||
Preferred Stock, Shares Outstanding, Ending Balance (in shares) | 31,678 | 35,819 | 31,678 | 35,819 | |||||
Preferred Stock, Dividend Rate, Percentage | 12.50% | ||||||||
Preferred Stock Dividends, Shares (in shares) | 4,141 | 378 | 4,519 | ||||||
Dividends, Preferred Stock, Cash | $ 8,000 | $ 2,000 | $ 10,000 | ||||||
Preferred Stock, Fair Value, Per Share (in dollars per share) | $ 1,023.23 | ||||||||
Convertible Preferred Stock, Fair Value | $ 32,027,000 | ||||||||
Stock Issued During Period, Shares, Conversion of Convertible Securities (in shares) | 31,300 |
Note 12 - Common Stock (Details
Note 12 - Common Stock (Details Textual) | Jun. 09, 2020USD ($)$ / sharesshares | Jun. 08, 2020USD ($) | Apr. 20, 2020USD ($)$ / sharesshares | Apr. 16, 2020USD ($)shares | Sep. 30, 2020USD ($)shares | Aug. 31, 2020USD ($)shares | Jun. 30, 2020USD ($)shares | May 31, 2020USD ($)shares | Mar. 31, 2020USD ($)shares | Feb. 29, 2020USD ($)shares | Dec. 31, 2019USD ($)$ / sharesshares | Nov. 30, 2019USD ($)$ / sharesshares | Oct. 31, 2019USD ($)shares | Aug. 31, 2019USD ($) | Mar. 31, 2019USD ($)shares | Nov. 30, 2019USD ($)$ / sharesshares | Dec. 31, 2020USD ($)shares | Dec. 31, 2019USD ($)$ / sharesshares | Dec. 16, 2020shares | Apr. 15, 2020$ / shares | Nov. 12, 2019USD ($)$ / sharesshares | May 22, 2017USD ($)$ / sharesshares |
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 2,473,785 | 2,473,785 | ||||||||||||||||||||
Stock Issued During Period, Share, Restricted Common Shares (in shares) | 4,709 | 3,453 | 2,832 | 3,068 | 774 | 28 | ||||||||||||||||
Stock Issued During Period, Value, Restricted Common Shares | $ | $ 25,000 | $ 25,000 | $ 24,000 | $ 25,000 | $ 25,000 | $ 25,000 | $ 74,000 | $ 75,000 | ||||||||||||||
Warrants and Rights Outstanding | $ | $ 3,502,000 | 3,502,000 | ||||||||||||||||||||
Proceeds from Warrant Exercises | $ | 8,407,000 | |||||||||||||||||||||
Fair Value Adjustment of Warrants | $ | 1,838,000 | |||||||||||||||||||||
Payments of Warrant Issuance Costs | $ | $ 334,000 | 334,000 | ||||||||||||||||||||
Amortization of Debt Discount (Premium) | $ | 3,000 | $ 352,000 | ||||||||||||||||||||
Debt Instrument, Unamortized Discount, Total | $ | $ 9,000 | |||||||||||||||||||||
Class of Warrants or Rights, Exercises in Period (in shares) | 1,209,000 | 0 | ||||||||||||||||||||
Class of Warrant or Right Number of Securities Called by Warrants or Rights Cancelled In Period (in shares) | 0 | 0 | ||||||||||||||||||||
Class Of Warrant Or Right, Number Of Securities Called By Warrants Or Rights Expired In Period (in shares) | 42,404 | 140 | ||||||||||||||||||||
The 2017 Loan Agreement [Member] | ||||||||||||||||||||||
Debt Issuance Costs, Net, Total | $ | $ 790,000 | |||||||||||||||||||||
Debt Instrument, Unamortized Discount, Total | $ | $ 9,000 | |||||||||||||||||||||
Series B Convertible Preferred Stock Into Common Stock [Member] | Minimum [Member] | ||||||||||||||||||||||
Conversion of Stock, Conversion Rate (in dollars per share) | $ / shares | $ 15.30 | |||||||||||||||||||||
Series B Convertible Preferred Stock Into Common Stock [Member] | Maximum [Member] | ||||||||||||||||||||||
Conversion of Stock, Conversion Rate (in dollars per share) | $ / shares | $ 18.36 | |||||||||||||||||||||
Series A Preferred Stock [Member] | ||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 547,345 | |||||||||||||||||||||
Convertible Preferred Stock, Shares Issued upon Conversion (in shares) | 1 | 1 | 1 | 1 | 1 | |||||||||||||||||
Preferred Stock, Shares Outstanding, Ending Balance (in shares) | 185,218 | 0 | 185,218 | 0 | ||||||||||||||||||
Series A Warrants [Member] | ||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | 1 | ||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 18.36 | $ 15.50 | $ 15.50 | $ 18.36 | ||||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 1 year | 1 year | ||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 989,379 | 741,939 | 741,939 | 989,379 | ||||||||||||||||||
Warrants and Rights Outstanding | $ | $ 1,210,000 | $ 1,210,000 | ||||||||||||||||||||
Stock Issued During Period, Shares, Warrant Exercises (in shares) | 482,059 | 111,704 | 2,761 | 410 | 102,626 | |||||||||||||||||
Proceeds from Warrant Exercises | $ | $ 681,000 | $ 17,000 | $ 2,000 | $ 1,591,000 | ||||||||||||||||||
Class of Warrant or Right, Outstanding (in shares) | 0 | |||||||||||||||||||||
Series A Warrants [Member] | Measurement Input, Expected Dividend Rate [Member] | ||||||||||||||||||||||
Warrants and Rights Outstanding, Measurement Input | 0 | 0 | ||||||||||||||||||||
Series A Warrants [Member] | Measurement Input, Price Volatility [Member] | ||||||||||||||||||||||
Warrants and Rights Outstanding, Measurement Input | 91.1 | 91.1 | ||||||||||||||||||||
Series A Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member] | ||||||||||||||||||||||
Warrants and Rights Outstanding, Measurement Input | 1.59 | 1.59 | ||||||||||||||||||||
Series A Warrants [Member] | Measurement Input, Expected Term [Member] | ||||||||||||||||||||||
Warrants and Rights Outstanding, Measurement Input | 1 | 1 | ||||||||||||||||||||
Series B Warrants [Member] | ||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | 1 | ||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 15.50 | $ 15.50 | $ 15.50 | $ 15.50 | ||||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | 5 years | ||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 741,940 | 741,939 | 741,939 | 325,632 | 741,940 | |||||||||||||||||
Warrants and Rights Outstanding | $ | $ 2,871,000 | $ 2,871,000 | ||||||||||||||||||||
Stock Issued During Period, Shares, Warrant Exercises (in shares) | 24,279 | 1,500 | 380,913 | 5,070 | 4,548 | |||||||||||||||||
Proceeds from Warrant Exercises | $ | $ 9,000 | $ 2,324,000 | $ 31,000 | $ 70,000 | ||||||||||||||||||
Class of Warrant or Right, Outstanding (in shares) | 325,632 | |||||||||||||||||||||
Series B Warrants [Member] | Measurement Input, Expected Dividend Rate [Member] | ||||||||||||||||||||||
Warrants and Rights Outstanding, Measurement Input | 0 | 0 | ||||||||||||||||||||
Series B Warrants [Member] | Measurement Input, Price Volatility [Member] | ||||||||||||||||||||||
Warrants and Rights Outstanding, Measurement Input | 0.688 | 0.688 | ||||||||||||||||||||
Series B Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member] | ||||||||||||||||||||||
Warrants and Rights Outstanding, Measurement Input | 0.0158 | 0.0158 | ||||||||||||||||||||
Series B Warrants [Member] | Measurement Input, Expected Term [Member] | ||||||||||||||||||||||
Warrants and Rights Outstanding, Measurement Input | 5 | 5 | ||||||||||||||||||||
Series A and Series B Warrants [Member] | ||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 15.50 | $ 15.50 | $ 6.10 | |||||||||||||||||||
Warrants and Rights Outstanding | $ | $ 4,081,000 | $ 4,081,000 | ||||||||||||||||||||
Proceeds from Warrant Exercises | $ | $ 3,089,000 | |||||||||||||||||||||
Series A-2 Warrants [Member] | ||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 482,059 | 392,830 | ||||||||||||||||||||
Stock Issued During Period, Shares, Warrant Exercises (in shares) | 89,230 | 392,830 | ||||||||||||||||||||
Proceeds from Warrant Exercises | $ | $ 568,000 | |||||||||||||||||||||
Series B-2 Warrants [Member] | ||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 24,279 | 20,380 | ||||||||||||||||||||
Stock Issued During Period, Shares, Warrant Exercises (in shares) | 3,899 | 20,380 | ||||||||||||||||||||
Proceeds from Warrant Exercises | $ | $ 25,000 | |||||||||||||||||||||
Series A-2 and Series B-2 Warrants [Member] | ||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 6.371 | |||||||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | |||||||||||||||||||||
Class of Warrant or Right, Outstanding (in shares) | 1,838,000 | |||||||||||||||||||||
Series A-2 and Series B-2 Warrants [Member] | Measurement Input, Expected Dividend Rate [Member] | ||||||||||||||||||||||
Warrants and Rights Outstanding, Measurement Input | 0 | |||||||||||||||||||||
Series A-2 and Series B-2 Warrants [Member] | Measurement Input, Price Volatility [Member] | ||||||||||||||||||||||
Warrants and Rights Outstanding, Measurement Input | 0.00841 | |||||||||||||||||||||
Series A-2 and Series B-2 Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member] | ||||||||||||||||||||||
Warrants and Rights Outstanding, Measurement Input | 0.35 | |||||||||||||||||||||
Series A-2 and Series B-2 Warrants [Member] | Measurement Input, Expected Term [Member] | ||||||||||||||||||||||
Warrants and Rights Outstanding, Measurement Input | 5 | |||||||||||||||||||||
Warrants Issued Upon Conversion of Term Loan with CRG [Member] | ||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 15.50 | $ 15.50 | ||||||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | |||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 741,940 | 741,940 | 989,379 | |||||||||||||||||||
Warrants and Rights Outstanding | $ | $ 3,502,000 | |||||||||||||||||||||
Class of Warrants or Rights, Outstanding, Percentage of Common Stock | 15.00% | |||||||||||||||||||||
Class of Warrants and Rights Outstanding, Exercise Price Percentage of Conversion Rate | 120.00% | |||||||||||||||||||||
Warrants Issued Upon Conversion of Term Loan with CRG [Member] | Measurement Input, Expected Dividend Rate [Member] | ||||||||||||||||||||||
Warrants and Rights Outstanding, Measurement Input | 0 | |||||||||||||||||||||
Warrants Issued Upon Conversion of Term Loan with CRG [Member] | Measurement Input, Price Volatility [Member] | ||||||||||||||||||||||
Warrants and Rights Outstanding, Measurement Input | 0.688 | |||||||||||||||||||||
Warrants Issued Upon Conversion of Term Loan with CRG [Member] | Measurement Input, Risk Free Interest Rate [Member] | ||||||||||||||||||||||
Warrants and Rights Outstanding, Measurement Input | 0.0158 | |||||||||||||||||||||
Warrants Issued Upon Conversion of Term Loan with CRG [Member] | Measurement Input, Expected Term [Member] | ||||||||||||||||||||||
Warrants and Rights Outstanding, Measurement Input | 5 | |||||||||||||||||||||
May 2017 Issuance Related to 2017 Loan Agreement [Member] | ||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 9,500 | $ 9,500 | $ 9,500 | |||||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 10 years | |||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 223 | 223 | 223 | |||||||||||||||||||
Warrants and Rights Outstanding | $ | $ 940,000 | |||||||||||||||||||||
May 2017 Issuance Related to 2017 Loan Agreement [Member] | Measurement Input, Expected Dividend Rate [Member] | ||||||||||||||||||||||
Warrants and Rights Outstanding, Measurement Input | 0 | |||||||||||||||||||||
May 2017 Issuance Related to 2017 Loan Agreement [Member] | Measurement Input, Price Volatility [Member] | ||||||||||||||||||||||
Warrants and Rights Outstanding, Measurement Input | 55.1 | |||||||||||||||||||||
May 2017 Issuance Related to 2017 Loan Agreement [Member] | Measurement Input, Risk Free Interest Rate [Member] | ||||||||||||||||||||||
Warrants and Rights Outstanding, Measurement Input | 2.25 | |||||||||||||||||||||
May 2017 Issuance Related to 2017 Loan Agreement [Member] | Measurement Input, Expected Term [Member] | ||||||||||||||||||||||
Warrants and Rights Outstanding, Measurement Input | 10 | |||||||||||||||||||||
Class A Units [Member] | Series A Warrants [Member] | ||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | 1 | ||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 15.50 | $ 15.50 | ||||||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 1 year | 1 year | ||||||||||||||||||||
Class A Units [Member] | Series B Warrants [Member] | ||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | 1 | ||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 15.50 | $ 15.50 | ||||||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | 5 years | ||||||||||||||||||||
Class B Units [Member] | Series A Warrants [Member] | ||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | 1 | ||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 15.50 | $ 15.50 | ||||||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 1 year | 1 year | ||||||||||||||||||||
Class B Units [Member] | Series B Warrants [Member] | ||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | 1 | ||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares | $ 15.50 | $ 15.50 | ||||||||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | 5 years | ||||||||||||||||||||
Common Stock [Member] | ||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 52,500 | |||||||||||||||||||||
Stock Issued During Period, Share, Restricted Common Shares (in shares) | 10,995 | 3,869 | ||||||||||||||||||||
Stock Issued During Period, Value, Restricted Common Shares | $ | ||||||||||||||||||||||
Common Stock [Member] | Series A and Series B Warrants [Member] | ||||||||||||||||||||||
Stock Issued During Period, Shares, Warrant Exercises (in shares) | 1,115,863 | |||||||||||||||||||||
Common Stock [Member] | Series A-2 and Series B-2 Warrants [Member] | ||||||||||||||||||||||
Stock Issued During Period, Shares, Warrant Exercises (in shares) | 93,129 | |||||||||||||||||||||
Purchase Agreement with LPC [Member] | ||||||||||||||||||||||
Maximum Amount of Shares Issuable | $ | $ 10,000,000 | |||||||||||||||||||||
Stock Purchase Agreement Duration Period (Month) | 2 years 180 days | |||||||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 52,500 | |||||||||||||||||||||
Shares Issued, Price Per Share (in dollars per share) | $ / shares | $ 6.50 | |||||||||||||||||||||
Maximum Number of Shares Issuable on Any Business Day Selected by The Company (in shares) | 25,000 | |||||||||||||||||||||
Maximum Number of Shares Issuable on Regular Purchase, Closing Sale Price Not Below $10.00 (in shares) | 30,000 | |||||||||||||||||||||
Maximum Number of Shares Issuable on Regular Purchase, Closing Sale Price Not Below $20.00 (in shares) | 50,000 | |||||||||||||||||||||
Maximum Number of Shares Issuable Any single Regular Purchase (in shares) | 1,000,000 | |||||||||||||||||||||
Payments of Stock Issuance Costs | $ | $ 494,000 | $ 494,000 | ||||||||||||||||||||
Purchase Agreement with LPC [Member] | Commitment Fee [Member] | ||||||||||||||||||||||
Payments of Stock Issuance Costs | $ | $ 325,000 | |||||||||||||||||||||
November 2019 Offering [Member] | ||||||||||||||||||||||
Shares Issued, Price Per Share (in dollars per share) | $ / shares | $ 15.50 | $ 15.50 | ||||||||||||||||||||
Payments of Stock Issuance Costs | $ | $ 33,000 | |||||||||||||||||||||
Proceeds from Issuance or Sale of Equity, Total | $ | $ 11,500,000 | |||||||||||||||||||||
Proceeds From Issuance of Common Stock, Net | $ | $ 9,922,000 | |||||||||||||||||||||
Common Shares Per Unit (in shares) | 1 | 1 | ||||||||||||||||||||
November 2019 Offering [Member] | Series A Preferred Stock [Member] | ||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 547,345 | 547,341 | ||||||||||||||||||||
November 2019 Offering [Member] | Class A Units [Member] | ||||||||||||||||||||||
Shares Issued, Price Per Share (in dollars per share) | $ / shares | $ 15.50 | $ 15.50 | ||||||||||||||||||||
Common Shares Per Unit (in shares) | 1 | 1 | ||||||||||||||||||||
November 2019 Offering [Member] | Class B Units [Member] | ||||||||||||||||||||||
Shares Issued, Price Per Share (in dollars per share) | $ / shares | $ 15.50 | $ 15.50 | ||||||||||||||||||||
Series A Convertible Preferred Stock Per Unit (in shares) | 1 | 1 | ||||||||||||||||||||
November 2019 Offering [Member] | Class B Units [Member] | Series A Preferred Stock [Member] | ||||||||||||||||||||||
Convertible Preferred Stock, Shares Issued upon Conversion (in shares) | 1 | 1 | ||||||||||||||||||||
November 2019 Offering [Member] | Common Stock [Member] | ||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 194,595 | 194,595 | 194,595 | |||||||||||||||||||
August 2019 ATM Facility [Member] | ||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 100,423 | |||||||||||||||||||||
Proceeds From Issuance of Common Stock, Net | $ | $ 6,322,000 | |||||||||||||||||||||
Aggregate Offering Price | $ | $ 6,760,000 | |||||||||||||||||||||
Common Stock, Shares, Remaining Shares to be Issued (in shares) | 0 | 0 | ||||||||||||||||||||
August 2019 ATM Facility [Member] | Common Stock [Member] | ||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 100,418 | |||||||||||||||||||||
November 2017 ATM Facility [Member] | ||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 0 | |||||||||||||||||||||
Aggregate Offering Price | $ | $ 25,000,000 |
Note 12 - Common Stock - Summar
Note 12 - Common Stock - Summary of Outstanding Warrants (Details) - $ / shares | 12 Months Ended | ||||
Dec. 31, 2020 | Dec. 31, 2019 | Nov. 30, 2019 | Nov. 12, 2019 | May 22, 2017 | |
Shares Outstanding Under Warrants (in shares) | 2,473,785 | ||||
Warrant One [Member] | |||||
Expiration Date | Feb. 17, 2025 | ||||
Exercise Price (in dollars per share) | $ 4,000 | ||||
Shares Outstanding Under Warrants (in shares) | 79 | ||||
Employee Performance Bonus Warrants, February 2015 Issuance [Member] | |||||
Expiration Date | Feb. 17, 2025 | ||||
Exercise Price (in dollars per share) | $ 4,000 | ||||
Shares Outstanding Under Warrants (in shares) | 79 | ||||
Warrant Two [Member] | |||||
Expiration Date | Mar. 26, 2025 | ||||
Exercise Price (in dollars per share) | $ 2,720 | ||||
Shares Outstanding Under Warrants (in shares) | 2 | ||||
Contractor Warrants, March 2015 Issuance [Member] | |||||
Expiration Date | Mar. 26, 2025 | ||||
Exercise Price (in dollars per share) | $ 2,720 | ||||
Shares Outstanding Under Warrants (in shares) | 2 | ||||
Warrant Three [Member] | |||||
Expiration Date | May 12, 2025 | ||||
Exercise Price (in dollars per share) | $ 4,240 | ||||
Shares Outstanding Under Warrants (in shares) | 37 | ||||
Contractor Warrants, May 2015 Issuance [Member] | |||||
Expiration Date | May 12, 2025 | ||||
Exercise Price (in dollars per share) | $ 4,240 | ||||
Shares Outstanding Under Warrants (in shares) | 37 | ||||
Warrant Four [Member] | |||||
Expiration Date | Dec. 16, 2025 | ||||
Exercise Price (in dollars per share) | $ 5,600 | ||||
Shares Outstanding Under Warrants (in shares) | 31 | ||||
May 2015 Issuance Second Contractor [Member] | |||||
Expiration Date | May 17, 2020 | ||||
Exercise Price (in dollars per share) | $ 4,240 | ||||
Shares Outstanding Under Warrants (in shares) | 22 | ||||
Warrant Five [Member] | |||||
Expiration Date | Apr. 1, 2026 | ||||
Exercise Price (in dollars per share) | $ 6,080 | ||||
Shares Outstanding Under Warrants (in shares) | 25 | ||||
Performance Bonus Warrants, December 2015 Issuance [Member] | |||||
Expiration Date | Dec. 16, 2025 | ||||
Exercise Price (in dollars per share) | $ 5,600 | ||||
Shares Outstanding Under Warrants (in shares) | 31 | ||||
Warrant Six [Member] | |||||
Expiration Date | May 11, 2021 | ||||
Exercise Price (in dollars per share) | $ 7,740 | ||||
Shares Outstanding Under Warrants (in shares) | 6 | ||||
Distributor Warrants, April 2016 Issuance [Member] | |||||
Expiration Date | Apr. 1, 2026 | ||||
Exercise Price (in dollars per share) | $ 6,080 | ||||
Shares Outstanding Under Warrants (in shares) | 25 | ||||
Warrant Seven [Member] | |||||
Expiration Date | Jun. 20, 2026 | ||||
Exercise Price (in dollars per share) | $ 4,980 | ||||
Shares Outstanding Under Warrants (in shares) | 101 | ||||
Contractor Warrants, May 2016 Issuance [Member] | |||||
Expiration Date | May 11, 2021 | ||||
Exercise Price (in dollars per share) | $ 7,740 | ||||
Shares Outstanding Under Warrants (in shares) | 6 | ||||
Warrant Eight [Member] | |||||
Expiration Date | May 25, 2027 | ||||
Exercise Price (in dollars per share) | $ 9,500 | ||||
Shares Outstanding Under Warrants (in shares) | 223 | ||||
June 2016 Issuance Related to 2016 Loan Agreement [Member] | |||||
Expiration Date | Jun. 20, 2026 | ||||
Exercise Price (in dollars per share) | $ 4,980 | ||||
Shares Outstanding Under Warrants (in shares) | 101 | ||||
Warrant Nine [Member] | |||||
Expiration Date | Nov. 26, 2024 | ||||
Exercise Price (in dollars per share) | $ 6.10 | ||||
Shares Outstanding Under Warrants (in shares) | 325,632 | ||||
May 2017 Issuance Related to 2017 Loan Agreement [Member] | |||||
Expiration Date | May 25, 2027 | ||||
Exercise Price (in dollars per share) | $ 9,500 | $ 9,500 | |||
Shares Outstanding Under Warrants (in shares) | 223 | 223 | |||
Warrant Ten [Member] | |||||
Expiration Date | Nov. 26, 2024 | ||||
Exercise Price (in dollars per share) | $ 18.36 | ||||
Shares Outstanding Under Warrants (in shares) | 989,379 | ||||
Series A Warrants [Member] | |||||
Expiration Date | Nov. 26, 2020 | ||||
Exercise Price (in dollars per share) | $ 18.36 | $ 15.50 | |||
Shares Outstanding Under Warrants (in shares) | 989,379 | 741,939 | |||
Warrant Eleven [Member] | |||||
Expiration Date | Apr. 21, 2025 | ||||
Exercise Price (in dollars per share) | $ 6.37 | ||||
Shares Outstanding Under Warrants (in shares) | 413,210 | ||||
Series B Warrants [Member] | |||||
Expiration Date | Nov. 26, 2024 | ||||
Exercise Price (in dollars per share) | $ 15.50 | $ 15.50 | |||
Shares Outstanding Under Warrants (in shares) | 325,632 | 741,940 | 741,939 | ||
Warrants Issued Upon Conversion of Term Loan with CRG [Member] | |||||
Expiration Date | Nov. 26, 2024 | ||||
Exercise Price (in dollars per share) | $ 15.50 | ||||
Shares Outstanding Under Warrants (in shares) | 741,940 | 989,379 | |||
Warrant Twelve [Member] | |||||
Shares Outstanding Under Warrants (in shares) | 1,728,725 |
Note 12 - Common Stock - Assump
Note 12 - Common Stock - Assumptions (Details) - Warrant [Member] | Apr. 15, 2020 | Apr. 14, 2020 |
Measurement Input, Exercise Price [Member] | ||
Warrants and Rights Outstanding, Measurement Input | 6.1 | 15.5 |
Measurement Input, Share Price [Member] | ||
Warrants and Rights Outstanding, Measurement Input | 6.3 | 6.3 |
Measurement Input, Expected Term [Member] | ||
Warrants and Rights Outstanding, Measurement Input | 2.8 | 2.8 |
Measurement Input, Price Volatility [Member] | ||
Warrants and Rights Outstanding, Measurement Input | 0.97 | 0.97 |
Measurement Input, Risk Free Interest Rate [Member] | ||
Warrants and Rights Outstanding, Measurement Input | 0.0027 | 0.0027 |
Measurement Input, Expected Dividend Rate [Member] | ||
Warrants and Rights Outstanding, Measurement Input | 0 | 0 |
Note 13 - Summary of Stock Op_3
Note 13 - Summary of Stock Options (Details Textual) - USD ($) | Aug. 22, 2016 | Jun. 30, 2020 | Jan. 31, 2020 | Sep. 30, 2019 | Jul. 31, 2019 | Jun. 30, 2019 | Apr. 30, 2019 | Jan. 31, 2019 | Aug. 31, 2017 | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | Jan. 01, 2020 | Nov. 26, 2019 | Jan. 01, 2019 |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares) | 986,399 | 1,008,833 | 4,098 | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share) | $ 19.10 | $ 22.47 | $ 4,567.36 | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year) | 8 years 328 days | 9 years 328 days | 7 years 146 days | ||||||||||||
Proceeds from Stock Plans | $ 56,000 | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares) | 146,700 | 1,006,602 | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares) | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate | |||||||||||||||
Consultant [Member] | |||||||||||||||
Stock Issued During Period, Shares, Restricted Stock Award, Gross (in shares) | 25 | 25 | |||||||||||||
Director [Member] | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 38 | 53 | |||||||||||||
Stock Issued During Period, Shares, Restricted Stock Award, Gross (in shares) | 38 | 53 | |||||||||||||
Restricted Stock [Member] | Director [Member] | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) | $ 380.80 | $ 910 | |||||||||||||
Share-based Payment Arrangement, Option [Member] | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate | 0.00% | ||||||||||||||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total | $ 4,781,000 | ||||||||||||||
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) | 2 years 182 days | ||||||||||||||
The 2006 Stock Option Plan [Member] | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares) | 12 | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares) | 0 | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share) | $ 9,920 | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year) | 2 years 36 days | ||||||||||||||
The 2013 Plan [Member] | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares) | 986,387 | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares) | 466,200 | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share) | $ 18.98 | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year) | 8 years 328 days | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year) | 10 years | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year) | 4 years | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum | 10.00% | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent | 110.00% | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized, Percentage Increase of Outstanding Common Stock | 4.00% | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares) | 263,993 | 2,044 | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares) | 1,451,246 | 4,914 | 1,451,246 | 1,187,253 | 6,958 | ||||||||||
Common Stock Shares Reserved For Future Issuance Percentage | 18.00% | ||||||||||||||
The 2013 Plan [Member] | Employees and Nonemployees [Member] | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares) | 146,700 | 1,006,602 | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) | $ 4.08 | $ 7.23 | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares) | 0 | 0 | |||||||||||||
The 2013 Plan [Member] | Restricted Stock [Member] | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance (in shares) | 234 | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 384 | 0 | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period (in shares) | 18 | 132 | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares) | 0 | ||||||||||||||
The 2013 Plan [Member] | Underwritten Public Offering [Member] | |||||||||||||||
Minimum Gross Proceeds From Equity Offering Amount Used In Calculation Of Reserved Shares Percentage | $ 5,000,000 | ||||||||||||||
The 2013 Plan [Member] | Holdings Greater Than 10 Percent of Shares Outstanding [Member] | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year) | 5 years | ||||||||||||||
2017 Employee Stock Purchase Plan [Member] | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent | 85.00% | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares Per Employee (in shares) | 200 | ||||||||||||||
Stock Issued During Period, Shares, Employee Stock Purchase Plans (in shares) | 84 | 154 | |||||||||||||
Proceeds from Stock Plans | $ 1,000 | $ 56,000 | |||||||||||||
Employee Stock Ownership Plan (ESOP), Number of Suspense Shares (in shares) | 22 |
Note 13 - Summary of Stock Op_4
Note 13 - Summary of Stock Options - Summary of Option Activity Under All Plans (Details) - USD ($) | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Options outstanding (in shares) | 1,008,833 | 4,098 | |
Options outstanding, weighted average exercise price (in dollars per share) | $ 22.47 | $ 4,567.36 | |
Options outstanding, weighted average remaining contractual term (Year) | 8 years 328 days | 9 years 328 days | 7 years 146 days |
Options outstanding, aggregate intrinsic value | $ 675,000 | $ 3,928,715,000 | |
Options granted (in shares) | 146,700 | 1,006,602 | |
Options granted, weighted average exercise price (in dollars per share) | $ 6.36 | $ 11.42 | |
Options exercised (in shares) | |||
Options exercised, weighted average exercise price (in dollars per share) | |||
Options canceled (in shares) | (169,134) | (1,867) | |
Options canceled, weighted average exercise price (in dollars per share) | $ 28.45 | $ 4,040.64 | |
Options outstanding (in shares) | 986,399 | 1,008,833 | 4,098 |
Options outstanding, weighted average exercise price (in dollars per share) | $ 19.10 | $ 22.47 | $ 4,567.36 |
Vested and exercisable and expected to vest (in shares) | 923,646 | ||
Vested and exercisable and expected to vest, end of period, weighted average exercise price (in dollars per share) | $ 19.77 | ||
Vested and exercisable and expected to vest, end of period, weighted average remaining contractual term (Year) | 8 years 328 days | ||
Vested and exercisable and expected to vest, end of period, aggregate intrinsic value | $ 598 | ||
Vested and exercisable (in shares) | 245,445 | ||
Vested and exercisable, end of period, weighted average exercise price (in dollars per share) | $ 45.09 | ||
Vested and exercisable, end of period, weighted average remaining contractual term (Year) | 8 years 219 days | ||
Vested and exercisable, end of period, aggregate intrinsic value |
Note 13 - Summary of Stock Op_5
Note 13 - Summary of Stock Options - Summary of Options Outstanding and Exercisable (Details) | 12 Months Ended |
Dec. 31, 2020$ / sharesshares | |
Options outstanding, number (in shares) | shares | 986,399 |
Options outstanding, weighted average exercise price (in dollars per share) | $ 19.10 |
Options outstanding, weighted average remaining contractual term (Year) | 8 years 328 days |
Options exercisable, number exercisable (in shares) | shares | 245,445 |
Options exercisable, weighted average exercise price (in dollars per share) | $ 45.09 |
Range One [Member] | |
Exercise price range, lower limit (in dollars per share) | 4.45 |
Exercise price range, upper limit (in dollars per share) | $ 8.91 |
Options outstanding, number (in shares) | shares | 967,288 |
Options outstanding, weighted average exercise price (in dollars per share) | $ 8.32 |
Options outstanding, weighted average remaining contractual term (Year) | 8 years 328 days |
Options exercisable, number exercisable (in shares) | shares | 238,900 |
Options exercisable, weighted average exercise price (in dollars per share) | $ 8.69 |
Range Two [Member] | |
Exercise price range, lower limit (in dollars per share) | 10.90 |
Exercise price range, upper limit (in dollars per share) | $ 13.60 |
Options outstanding, number (in shares) | shares | 15,500 |
Options outstanding, weighted average exercise price (in dollars per share) | $ 12.64 |
Options outstanding, weighted average remaining contractual term (Year) | 9 years 73 days |
Options exercisable, number exercisable (in shares) | shares | 3,750 |
Options exercisable, weighted average exercise price (in dollars per share) | $ 13.60 |
Range Three [Member] | |
Exercise price range, lower limit (in dollars per share) | 380 |
Exercise price range, upper limit (in dollars per share) | $ 580 |
Options outstanding, number (in shares) | shares | 125 |
Options outstanding, weighted average exercise price (in dollars per share) | $ 552 |
Options outstanding, weighted average remaining contractual term (Year) | 8 years 146 days |
Options exercisable, number exercisable (in shares) | shares | 113 |
Options exercisable, weighted average exercise price (in dollars per share) | $ 567.61 |
Range Four [Member] | |
Exercise price range, lower limit (in dollars per share) | 1,000 |
Exercise price range, upper limit (in dollars per share) | $ 1,970 |
Options outstanding, number (in shares) | shares | 1,954 |
Options outstanding, weighted average exercise price (in dollars per share) | $ 1,426.46 |
Options outstanding, weighted average remaining contractual term (Year) | 7 years 219 days |
Options exercisable, number exercisable (in shares) | shares | 1,334 |
Options exercisable, weighted average exercise price (in dollars per share) | $ 1,437.21 |
Range Five [Member] | |
Exercise price range, lower limit (in dollars per share) | 2,020 |
Exercise price range, upper limit (in dollars per share) | $ 2,830 |
Options outstanding, number (in shares) | shares | 74 |
Options outstanding, weighted average exercise price (in dollars per share) | $ 2,501.22 |
Options outstanding, weighted average remaining contractual term (Year) | 7 years |
Options exercisable, number exercisable (in shares) | shares | 53 |
Options exercisable, weighted average exercise price (in dollars per share) | $ 2,520.19 |
Range Six [Member] | |
Exercise price range, lower limit (in dollars per share) | 3,110 |
Exercise price range, upper limit (in dollars per share) | $ 3,580 |
Options outstanding, number (in shares) | shares | 189 |
Options outstanding, weighted average exercise price (in dollars per share) | $ 3,439.26 |
Options outstanding, weighted average remaining contractual term (Year) | 7 years 219 days |
Options exercisable, number exercisable (in shares) | shares | 156 |
Options exercisable, weighted average exercise price (in dollars per share) | $ 3,455.90 |
Range Seven [Member] | |
Exercise price range, lower limit (in dollars per share) | 4,360 |
Exercise price range, upper limit (in dollars per share) | $ 4,970 |
Options outstanding, number (in shares) | shares | 619 |
Options outstanding, weighted average exercise price (in dollars per share) | $ 4,549.77 |
Options outstanding, weighted average remaining contractual term (Year) | 6 years 73 days |
Options exercisable, number exercisable (in shares) | shares | 510 |
Options exercisable, weighted average exercise price (in dollars per share) | $ 4,554.04 |
Range Eight [Member] | |
Exercise price range, lower limit (in dollars per share) | 5,010 |
Exercise price range, upper limit (in dollars per share) | $ 5,670 |
Options outstanding, number (in shares) | shares | 300 |
Options outstanding, weighted average exercise price (in dollars per share) | $ 5,366 |
Options outstanding, weighted average remaining contractual term (Year) | 6 years 73 days |
Options exercisable, number exercisable (in shares) | shares | 285 |
Options exercisable, weighted average exercise price (in dollars per share) | $ 5,356.84 |
Range Nine [Member] | |
Exercise price range, lower limit (in dollars per share) | 6,000 |
Exercise price range, upper limit (in dollars per share) | $ 6,000 |
Options outstanding, number (in shares) | shares | 138 |
Options outstanding, weighted average exercise price (in dollars per share) | $ 6,000 |
Options outstanding, weighted average remaining contractual term (Year) | 5 years |
Options exercisable, number exercisable (in shares) | shares | 138 |
Options exercisable, weighted average exercise price (in dollars per share) | $ 6,000 |
Range Ten [Member] | |
Exercise price range, lower limit (in dollars per share) | 7,140 |
Exercise price range, upper limit (in dollars per share) | $ 7,920 |
Options outstanding, number (in shares) | shares | 200 |
Options outstanding, weighted average exercise price (in dollars per share) | $ 7,679.20 |
Options outstanding, weighted average remaining contractual term (Year) | 4 years 36 days |
Options exercisable, number exercisable (in shares) | shares | 194 |
Options exercisable, weighted average exercise price (in dollars per share) | $ 7,676.29 |
Range Eleven [Member] | |
Exercise price range, lower limit (in dollars per share) | 9,920 |
Exercise price range, upper limit (in dollars per share) | $ 9,920 |
Options outstanding, number (in shares) | shares | 12 |
Options outstanding, weighted average exercise price (in dollars per share) | $ 9,920 |
Options outstanding, weighted average remaining contractual term (Year) | 2 years 36 days |
Options exercisable, number exercisable (in shares) | shares | 12 |
Options exercisable, weighted average exercise price (in dollars per share) | $ 9,920 |
Note 13 - Summary of Stock Op_6
Note 13 - Summary of Stock Options - Valuation Assumptions for Stock Options (Details) | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Expected term (Year) | 5 years | 6 years |
Average volatility | 82.00% | 70.00% |
Risk-free interest rate | 0.37% | 1.62% |
Dividend yield |
Note 13 - Summary of Stock Op_7
Note 13 - Summary of Stock Options - Stock-based Compensation Expense Included in the Statement of Income (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Stock-based compensation expense | $ 2,651 | $ 2,400 |
Cost of Sales [Member] | ||
Stock-based compensation expense | 208 | 135 |
Research and Development Expense [Member] | ||
Stock-based compensation expense | 325 | 192 |
Selling, General and Administrative Expenses [Member] | ||
Stock-based compensation expense | $ 2,118 | $ 2,073 |
Note 14 - Income Taxes (Details
Note 14 - Income Taxes (Details Textual) - USD ($) xbrli-pure in Thousands | 12 Months Ended | ||
Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018 | |
Income Tax Expense (Benefit), Total | $ 0 | ||
Effective Income Tax Rate Reconciliation, Percent, Total | 0.00% | 0.00% | |
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount | $ 4,352,000 | $ (16,506,000) | |
Deferred Tax Assets, Tax Credit Carryforwards, Research | 631,000 | 527,000 | |
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total | 0 | ||
Unrecognized Tax Benefits, Ending Balance | 245,000 | $ 223,000 | $ 450,000 |
Domestic Tax Authority [Member] | |||
Operating Loss Carryforwards, Total | 95,395,000 | ||
State and Local Jurisdiction [Member] | |||
Operating Loss Carryforwards, Total | 20,239,000 | ||
State and Local Jurisdiction [Member] | California Franchise Tax Board [Member] | |||
Deferred Tax Assets, Tax Credit Carryforwards, Research | $ 817,000 |
Note 14 - Income Taxes - Provis
Note 14 - Income Taxes - Provision for Income Taxes Computed at Federal Statutory Rate (Details) | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Income tax benefit at statutory rate | (21.00%) | (21.00%) |
State income taxes, net of federal benefit | (3.00%) | (4.00%) |
Change in valuation allowance | 20.00% | (39.00%) |
Debt restructuring | 0.00% | 6.00% |
Limitation on net operating loss and credit carryovers | 0.00% | 56.00% |
Other | 4.00% | 2.00% |
Effective tax rate | 0.00% | 0.00% |
Note 14 - Income Taxes - Signif
Note 14 - Income Taxes - Significant Components of Deferred Tax Assets (Details) - USD ($) $ in Thousands | Dec. 31, 2020 | Dec. 31, 2019 |
Net operating loss carryforwards | $ 20,891 | $ 16,688 |
Capitalized start up costs | 2,866 | 3,225 |
Research and development credits | 631 | 527 |
Accruals and reserves | 773 | 532 |
Fixed assets and depreciation | (291) | (128) |
Total deferred tax assets | 25,452 | 21,100 |
Valuation allowance | (25,452) | (21,100) |
Net deferred tax assets |
Note 14 - Income Taxes - Unreco
Note 14 - Income Taxes - Unrecognized Tax Benefit Roll Forward (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Balance | $ 223,000 | $ 450,000 |
Additions (deletions) based upon tax positions related to the current year | 22,000 | (227,000) |
Balance | $ 245,000 | $ 223,000 |
Note 15 - Related Party Trans_2
Note 15 - Related Party Transactions (Details Textual) - Stellartech Research Corporation [Member] - USD ($) | 12 Months Ended | |
Dec. 31, 2020 | Dec. 31, 2019 | |
Stock Issued During Period, Shares, New Issues (in shares) | 38 | |
Related Party Transaction, Amounts of Transaction | $ 1,051,000 | $ 4,889,000 |
Note 16 - Segments and Geogra_3
Note 16 - Segments and Geographic Information (Details) - USD ($) $ in Thousands | Dec. 31, 2020 | Dec. 31, 2019 |
Long-lived assets | $ 2,759 | $ 3,046 |
UNITED STATES | ||
Long-lived assets | 2,622 | 2,818 |
Asia Pacific [Member] | ||
Long-lived assets | 76 | 64 |
CANADA | ||
Long-lived assets | 54 | 142 |
Europe [Member] | ||
Long-lived assets | $ 7 | $ 22 |
Note 17 - Subsequent Events (De
Note 17 - Subsequent Events (Details Textual) - USD ($) | Jan. 19, 2021 | Jan. 01, 2021 | Jun. 30, 2021 | Mar. 17, 2021 | Jan. 31, 2021 | Jan. 31, 2020 | Jan. 31, 2019 | Jan. 18, 2021 | Dec. 31, 2020 | Apr. 20, 2020 | Apr. 15, 2020 | Jan. 01, 2020 | Dec. 31, 2019 | Nov. 26, 2019 | Jan. 01, 2019 | Dec. 31, 2018 |
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 2,473,785 | |||||||||||||||
Sublease Agreement for Relocation of Headquarters [Member] | Forecast [Member] | ||||||||||||||||
Lessee, Operating Lease, Rent Abatement | $ 19,000 | |||||||||||||||
The 2013 Plan [Member] | ||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares) | 263,993 | 2,044 | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares) | 1,451,246 | 1,451,246 | 1,187,253 | 6,958 | 4,914 | |||||||||||
Series A-2 and Series B-2 Warrants [Member] | ||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 6.371 | |||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | |||||||||||||||
Series A and Series B Warrants [Member] | ||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 6.10 | $ 15.50 | ||||||||||||||
Subsequent Event [Member] | Sublease Agreement for Relocation of Headquarters [Member] | ||||||||||||||||
Lessee, Operating Lease, Renewal Term (Month) | 2 years 300 days | |||||||||||||||
Subsequent Event [Member] | Sublease Agreement for Relocation of Headquarters First Year Extension [Member] | ||||||||||||||||
Lessee, Operating Lease, Monthly Gross Rent | $ 21,028 | |||||||||||||||
Subsequent Event [Member] | Sublease Agreement for Relocation of Headquarters Second Year Extension [Member] | ||||||||||||||||
Lessee, Operating Lease, Monthly Gross Rent | 21,643 | |||||||||||||||
Subsequent Event [Member] | Sublease Agreement for Relocation of Headquarters Third Year Extension [Member] | ||||||||||||||||
Lessee, Operating Lease, Monthly Gross Rent | $ 22,258 | |||||||||||||||
Subsequent Event [Member] | Restricted Stock Units (RSUs) [Member] | ||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) | 690,000 | |||||||||||||||
Subsequent Event [Member] | The 2013 Plan [Member] | ||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares) | 307,705 | |||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares) | 1,758,951 | |||||||||||||||
Subsequent Event [Member] | Series C Preferred Stock [Member] | ||||||||||||||||
Preferred Stock, Shares Outstanding, Ending Balance (in shares) | 0 | |||||||||||||||
Subsequent Event [Member] | Series A-2 and Series B-2 Warrants [Member] | ||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | |||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 3.40 | $ 6.371 | ||||||||||||||
Subsequent Event [Member] | Series A and Series B Warrants [Member] | ||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 3.40 | $ 6.10 | ||||||||||||||
Subsequent Event [Member] | Class A Units [Member] | Warrants Issued in Connection with Class A Units [Member] | ||||||||||||||||
Warrants Per Unit (in shares) | 1 | |||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | |||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 3.40 | |||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | |||||||||||||||
Subsequent Event [Member] | Class B Units [Member] | Warrants Issued in Connection with Class B Units [Member] | ||||||||||||||||
Warrants Per Unit (in shares) | 1 | |||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | 1 | |||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 3.40 | |||||||||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | |||||||||||||||
January 2021 Offering [Member] | Subsequent Event [Member] | ||||||||||||||||
Proceeds from Issuance or Sale of Equity, Total | $ 27,600,000 | |||||||||||||||
Shares Issued, Price Per Share (in dollars per share) | $ 3.40 | |||||||||||||||
Proceeds from Issuance or Sale of Equity, Net of Issuance Costs | $ 25,223,000 | |||||||||||||||
January 2021 Offering [Member] | Subsequent Event [Member] | Series C Preferred Stock [Member] | ||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 2,450,880 | |||||||||||||||
Convertible Preferred Stock, Shares Issued upon Conversion (in shares) | 1 | |||||||||||||||
January 2021 Offering [Member] | Subsequent Event [Member] | Class A Units [Member] | ||||||||||||||||
Units Issued, Shares (in shares) | 4,607,940 | |||||||||||||||
Shares Issued, Price Per Share (in dollars per share) | $ 3.40 | |||||||||||||||
Common Shares Per Unit (in shares) | 1 | |||||||||||||||
January 2021 Offering [Member] | Subsequent Event [Member] | Class B Units [Member] | ||||||||||||||||
Units Issued, Shares (in shares) | 2,450,880 | |||||||||||||||
Shares Issued, Price Per Share (in dollars per share) | $ 3.40 | |||||||||||||||
Series C Convertible Preferred Stock Per Unit (in shares) | 1 | |||||||||||||||
Over-Allotment Option [Member] | Subsequent Event [Member] | ||||||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 1,058,820 | |||||||||||||||
Over-Allotment Option [Member] | Subsequent Event [Member] | Warrants Issued in Connection with January 2021 Offering [Member] | ||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | 1,058,820 |